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In the presented study, we demonstrate that the alternative splicing of caspase 9
was dysregulated in a large percentage of NSCLC tumors and cell lines. These findings led
to the hypothesis that survival pathways activated by oncogenic mutation regulated this
mechanism. Indeed, the oncogenic PI3-Kinase/Akt pathway was demonstrated to regulate
the alternative splicing of caspase 9. Further mechanistic studies demonstrate that multiple
Akt isoforms can regulate the alternative splicing of caspase 9 in NSCLC. Akt was
additionally shown to mediate the exclusion of the exon 3,4,5,6 cassette of caspase 9 via
the phospho-state of the RNA trans-factor, SRp30a. Mutagenesis studies identified serine
199
, serine 201, serine 227, and serine 234 as critical residues regulating the alternative splicing
of caspase 9, as well as playing a role in the anchorage-independent growth of A549 cells.
Since dysregulation of this splicing mechanism correlated with NSCLC tumors/cell lines

and constitutively active Akt, oncogenic factors for NSCLC known to activate the PI3Kinase/Akt pathway were examined in HBEC-3KT cells. In contrast to k-ras
V12
expression, the overexpression/mutation of EGFR affected the alternative splicing of
caspase 9 in a pro-oncogenic manner, dramatically lowering the caspase 9a/9b mRNA
ratio. Stable downregulation of caspase 9b by shRNA blocked the ability of E746-A750
del EGFR expressing HBEC-3KTs to induce anchorage-independent growth, suggesting a
role for caspase 9b as a cooperative oncogenic factor. These findings were further
corroborated by the ability of caspase 9b expression to completely block the inhibition of
clonogenic colony formation by erlotinib. Therefore, this study demonstrates that
oncogenic factors activating the PI3-Kinase/Akt pathway regulate the alternative splicing
of caspase 9, to produce caspase 9b, via a coordinated mechanism involving the
phosphorylation of SRp30a. In additional studies, we demonstrate that the PI3Kinase/PKCη pathway, a pathway important for cancer cell survival and transformation of
lung epithelial cells, regulates the alternative splicing of Bcl-x pre-mRNA via modulation
of SAP155 expression to produce an anti-apoptotic phenotype in NSCLC. Therefore, these
studies link oncogenic mechanisms in NSCLC to the therapeutically relevant and distal
target mechanisms of caspase 9 and Bcl-x pre-mRNA splicing.

CHAPTER 1
INTRODUCTION

1.1. The pathways to cancer
Cancerous cells develop from healthy cells in a complex process called malignant
transformation or tumorigenesis. Several lines of evidence indicate that tumorigenesis in
humans is a multiple step process characterized by the loss of function of cellular
mechanisms that control normal proliferation and differentiation. It is predicted that by the
time a cancerous tumor becomes clinically evident, 10 to 20 genetic alterations of tumor
suppressor genes and/or proto-oncogenes have occurred, allowing for the transformation of
normal human cells into highly malignant derivatives1. While there are many distinct
types of cancer, six essential alterations to normal cell physiology are believed to be
responsible for the progression of most human malignancies: self-sufficiency in growth
signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative
potential, sustained angiogenesis, and tissue invasion and metastases2. Five physiologies
are described with examples to illustrate the functional importance.

1.1.1. Self sufficiency of growth signals
Mitogenic growth signals are required for a normal cell to enter an active
proliferative state. These signals are transmitted into the cell through transmembrane
1

2
receptors which are often targets of deregulation during tumorigenesis.

While most

mitogenic growth factors are produced by one cell in order to simulate a neighboring cell,
tumor cells generate many of their own growth signals to which they are responsive,
reducing their dependency on stimulation from the normal tissue microenvironment. This
creates a positive feedback signaling loop often termed autocrine stimulation.
Mitogenic signaling cascades are commonly upregulated in cancer via the
overexpression or mutation of growth factor receptors, often carrying tyrosine kinase
activities in their cytoplasmic domains.

Both gross over-expression and mutational

alteration of receptors can result in ligand-independent signaling leading to uncontrolled
cellular growth. The ERBB family is a group of transmembrane receptor tyrosine kinases
which, together with their ligands, constitutes a potential growth stimulatory loop,
particularly for non-small cell lung cancer (NSCLC).

The epidermal growth factor

receptor (EGFR) is one member of this family important in lung cancer. EGFR regulates
epithelial proliferation and differentiation, with ligands including epidermal growth factor
(EGF) and transforming growth factor-α (TGFα).
In addition to growth factors themselves, components downstream of growth factor
receptor signaling also play a pivotal role in a cell‘s ability to sustain growth signals.
Point mutations of Ras family proto-oncogenes (usually at k-Ras codons 12, 13, or 61) are
detected in approximately 30% of lung adenocarcinomas with a k-Ras mutation at codon
12 being most frequent3,4. Mutated Ras proteins are able to release a flux of mitogenic
signals without ongoing stimulation by their upstream regulators5.

Transgenic mice

carrying oncogenic alleles of k-Ras, activated only by spontaneous recombination events in
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the whole animal, were highly predisposed to a range of tumor types, predominantly early
onset lung cancer6. Clinically speaking, NSCLC patients with specific k-Ras point
mutations are associated with a significantly increased risk of tumor recurrence and death,
independent of tumor stage and histology7.
The three major Myc family members (c-Myc, N-Myc, and L-Myc) comprise yet
another important positive growth-regulatory system for lung cancer. The most frequently
dysregulated Myc family member in NSCLC is c-Myc, as opposed to N-Myc and L-Myc
which are generally activated only in SCLC8,9. Aberrant activation of c-Myc usually
occurs as a result of protein overexpression caused by gene amplification or by
transcriptional dysregulation10 and is found in 8 to 20% of NSCLCs8,11. Elevated or
deregulated expression of c-Myc has been detected in a wide range of human cancers and
is associated with aggressive and poorly differentiated tumors12-15.

1.1.2. Insensitivity to anti-growth signals
Within normal tissue, multiple anti-proliferation signals exist to maintain cellular
quiescence and tissue homeostasis. These growth-inhibitory signals can block proliferation
by either forcing cells into the G0 phase of the cell cycle or inducing terminal
differentiation resulting in cellular senescence. Developing cancers cells need to acquire
resistance to these anti-proliferative signals for further expansion.
At the molecular level, most anti-proliferative signals are funneled through the
protein products of tumor suppressor genes (TSGs). The tumor suppressor p53 has been
described as "the guardian of the genome," referring to its role in conserving stability by
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preventing genome mutation16. In response to DNA damage, p53 can induce growth arrest
by holding the cell cycle at the G1/S regulation checkpoint, allowing DNA repair proteins
to act. If DNA damage proves to be irreparable, p53 will initiate apoptosis. Therefore,
deregulation of p53 can allow for inappropriate survival of genetically damaged cells.
The p53 gene is the most frequently mutated TSG in human malignancy, detected
in 47% of 4,684 NSCLC tumors17. In 1999, Roth JA et al. provided clinical evidence of
p53‘s critical role in tumorigenesis18. Direct injection of wild-type p53 gene vectors into
human non-small cell lung tumors resulted in tumor regression and tumor growth
stabilization in some patients18.

These observations provided proof of principle that

correcting the p53 defect in the midst of a variety of genetic alterations could negate the
malignant phenotype.

1.1.3. Evasion of apoptosis
The expansion of tumor cell populations is not only the result of an increased rate
in cell proliferation but also of a decreased rate of cell removal. Apoptosis represents a
major source of the elimination of unwanted or unhealthy cells. The evidence is mounting,
principally from studies in mouse models and cultured cells, that acquired resistance
toward apoptosis is a hallmark of most and perhaps all types of cancer. A cell‘s fate to
proliferate or to engage in apoptosis is influenced by genes that contribute to the
development of cancer (oncogenes) and those that act to suppress tumor formation (tumor
suppressor genes). Oncogenes are mutated forms of normal cellular genes known as proto-
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oncogenes, which tend to operate as positive growth regulators and are involved in
promoting the differentiation and proliferation of normal cells. Tumor-suppressor genes
tend to have a dampening or repressive effect on the regulation of the cell cycle and/or
function to promote apoptosis.
Virtually all cancer cells harbor mutations that provide resistance to apoptosis,
which can be acquired through multiple strategies involving interplay between oncogenes
and tumor suppressor genes. The p53 tumor suppressor gene is the most commonly
mutated gene found in cancer, leaving more than 50% of all cancers with a loss of function
of the key pro-apoptotic regulator p5319,20. Other oncogenes such as Myc, Ras, and E1A
drive cellular proliferation in response to persistent and/or elevated signaling. However,
studies of Myc overexpression suggest that these oncogenes may affect apoptosis in
different ways, depending on certain circumstances. Myc, under conditions of severe
cellular stress or DNA damage, can act as a powerful inducer of apoptosis. However, the
pro-apoptotic effects of Myc is eliminated by exogenous survival factors such as IGF-1, by
overexpression of anti-apoptotic factors Bcl-2 and Bcl-XL, as well as by disruption of the
FAS death signaling circuit21.

Collectively, the data suggest that although a cell‘s

apoptotic program can be initiated by an overexpressed oncogene, other compounding
factors can attenuate such effects.
Another means by which cancer cells overcome apoptosis is through
hyperactivation of cell survival signaling. The anti-apoptotic PI3-Kinase/Akt survival
pathway is likely involved in mitigating apoptosis in a substantial fraction of human
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cancers. This mitogenic signaling pathway can be stimulated through extracellular factors
such as IGF-1/2, EGF, or IL-3, by intracellular signals triggered by oncogene Ras, or by
loss of the tumor suppressor gene PTEN, a negative regulator of the PI3-Kinase pathway.
Collectively, these observations argue that altering components of the apoptotic machinery
can dramatically affect the dynamics of tumor progression, providing a rationale for the
inactivation of this machinery during tumor development.

1.1.4. Limitless replicative potential
Research performed over the past 35 years indicate that acquired growth signal
autonomy, insensitivity of anti-growth signals, and a resistance to apoptosis is not enough
to ensure tumor growth. Many cells carry an intrinsic, cell-autonomous program that
limits infinite replication and this program must be disrupted to allow for large tumor
masses to develop. Senescence is the term used to describe the halt in proliferation that
most cell populations reach once progressed through a certain number of doublings.
Normal human cells, when cultured, have the capacity for 60-70 doublings. Mutations in
the tumor suppressor genes encoding pRb and p53 proteins are needed in order to
circumvent the cellular senescence of cultured human fibroblasts. These mutations enable
cultured human fibroblasts to continue multiplying for additional generations until a
―crisis‖ state is entered. The crisis state is characterized by massive cell death, karyotypic
disarray associated with end-to end fusion of chromosomes, and the occasional emergence
of a variant (1 in 107) cell that has acquired the ability to multiply without limit, termed
immortalization22. Most tumor cells that are cultured in vitro appear to be immortalized
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and have limitless replicative potential, suggesting that this phenotype was acquired in vivo
and was necessary to the development of the malignant growth23.
Telomeres are regions of a short 6 base pair sequence element located at the ends of
chromosomes. For each passage through the cell cycle, there is a 50-100 base pair loss of
telomeric DNA from the ends of every chromosome, attributing to the inability of DNA
polymerases to completely replicate the 3‘ ends of chromosomal DNA. Telomerase is an
enzyme that adds TTAGGG nucleotide repeats onto the ends of telomeric DNA. Normal
somatic cells do not posses telomerase activity and senesce when telomeres reach a critical
length.

However, 85-90% of malignant cells upregulate the expression of the telomerase

enzyme, providing a mechanism for infinite replicative potential24.

Previous studies

reveal that ectopically expressing telomerase induces immortalization onto a variety of
normal early passage, pre-senescent cell in vitro25,26. Additionally, late passage cells about
to enter the crisis state continued to proliferate when provided with telomerase enzyme27-29.
While telomerase activation is not the earliest step in the pathogenesis of cancer, it does
occur early enough to potentially serve as a biomarker detectable in pre-neoplastic cells.

1.1.5. Tissue invasion and metastases
It is inevitable, at some point in time a primary tumor mass will acquire the
capability to invade surrounding tissues and travel to distant sites where a secondary or
metastatic tumor will form. Tumor metastases, the spreading of tumor cells from one
tissue to a non-adjacent tissue, are the cause of 90% of human cancer deaths30. Like the
formation of the primary tumor, metastases rely on the acquisition of all five hallmark
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capabilities (four are discussed above). However, what additional changes must occur to
induce tissue invasion?
Cancerous cells exhibiting metastatic capabilities have altered cell-to-cell and cellto-environment interactions.

Most notably, the functions of cell-to-cell adhesion

molecules (CAMs) and the expression of integrins are modulated in cancer to support
tissue invasion. For example, the loss of function of E-cadherin, a cell-to-cell adhesion
molecule ubiquitiously expressed in epithelial cells, is commonly seen in cancers of
epithelial origin31.

Downregulation of E-cadherin decreases the strength of cellular

adhesion within a tissue, resulting in an increase in cellular motility. Furthermore, recent
reports have demonstrated that ectopic expression of E-cadherin in cultured cancer cells
and in a transgenic mouse model of carcinogenesis impairs invasion and metastatic
phenotypes31.
Invading cancer cells encounter a variety of different tissue microenvironments,
which all present different extracellular matrix (ECM) components.

Accordingly,

successful metastasis is achieved through shifts in the expression of integrins on the
migrating cancer cell. Integrins are a family of heterodimeric transmembrane adhesion
receptors that mediate cellular attachment to the ECM and to adjacent cells32. Research has
demonstrated that carcinoma cells switch their integrin profiles from those that favor the
ECM present in normal epithelium, to those that preferentially bind the degraded stromal
components produced by extracellular proteases33,34. Moreover, ectopic expression of
specific integrin subunits in cultured cells can inhibit or induce invasive behavior33.
Overall, it is well established that integrins, due to aberrant adhesive events and cellular
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signals that alter gene expression and influence cell survival, contribute to malignant
transformation, tumor growth and progression, and invasion and metastasis35-37. Thus, the
functional loss of E-cadherin and the switching of integrin profiles represent two key steps
in the acquisition of the ability of a cancer cell to metastasize.

1.2. Oncogenic pathways dysregulated in NSCLC
According to the World Health Organization, cancer is the leading cause of death
worldwide. In 2007 alone, it was estimated 7.9 million people died from cancer, a number
that is projected to increase 45% by 2030 (due in part to an increasing and aging
population)38. Of all cancers diagnosed, lung cancer is by far the most fatal, accounting for
29% of cancer deaths38.
The overwhelming majority of lung cancers diagnosed are classified as carcinomas
– malignancies that arise from epithelial cells. Depending of the size and appearance of
the malignant tumors, carcinomas can be characterized as non-small cell or small cell.
Non-small cell lung cancers (NSCLC) account for 80% of all lung cancers diagnosed. The
most common histologies of NSCLC are adenocarcinomas, squamous cell carcinomas
(also called epidermoid carcinoma), and large cell carcinomas. Adenocarcinomas are the
most frequent form of lung cancer and originate in the cells that line the alveoli; squamous
cell carcinomas originate in squamous cells and are generally found in the center of the
lung; and large cell carcinomas may begin in several types of large cells of the lung. Other
less common types of non-small cell lung cancer are: pleomorphic, carcinoid tumor,
salivary gland carcinoma, and unclassified carcinoma.
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Lung cancer is characterized by the accumulation of multiple genetic alterations
resulting in the activation of oncogenes or inactivation of tumor suppressor genes 39.
Dysregulation of epidermal growth factor receptor (EGFR) has been observed in multiple
cancers including NSCLC40.

Recently, Hirch et. al. reported that 62% of NSCLCs of

adenocarcinoma and squamous cell subtypes exhibited EGFR protein overexpression41,
which is often associated with poor prognosis42.

In addition to EGFR expression,

epidermal growth factor (EGF) and transforming growth factor-α (TGF-α), two of its
cognate ligands, are also freely expressed in NSCLCs, leading to over-stimulation of
downstream mitogenic signaling pathways43,44. Three prominent signaling networks
linking EGFR activation to cell proliferation and survival are the Ras/Raf/MEK/ERK
(Ras/MAPK), the PI3-Kinase/Akt pathway, and the PLCγ/PKC pathway.

These

pathways, with emphasis on the PI3-Kinase/Akt pathway, and their role in NSCLC will be
discussed.

1.2.1. The Ras/Raf/MEK/ERK pathway in NSCLC
MAPK (mitogen-activated protein kinase) pathways play critical roles in regulating
cellular proliferation, differentiation, and apoptosis45. Three major types of MAP kinase
cascades have been reported that respond synergistically to different upstream signals: the
classical MAPK (also known as ERK), c-Jun N-terminal kinase/stress-activated protein
kinase (JNK/SAPK), and p38 kinase. The extracellular signal-related kinase (ERK) has
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been the best characterized MAPK and the Raf-MEK-ERK pathway represents one of the
best characterized MAPK signaling pathways.
Activation of MEK or ERK results from stimulation of receptor tyrosine kinases by
growth factors such as EGF, HGF, and PGDF. It is also known that oncogenes such as
Ras can consititutively activate ERK, leading to malignant transformation in vitro and in
vivo46. Ras associates and activates Raf-1, which subsequently phosphorylates MEK,
which in turn phosphorylates ERK1/2. Activated ERK1/2 can then translocate to the
nucleus to modulate gene expression47,48. Ras signaling upon EGF stimulation has been
associated with increased cell growth and proliferation.
Constitutive activation of ERK and/or increased levels of ERK have been observed
in many tumor cell lines49 and in epithelial cancer tissues including breast50,51, kidney52,
colon53, and head and neck cancers54. Additionally, there is some evidence of ERK
activation in NSCLC primary cancers as compared to normal lung cells49,55. However, the
role of ERK activation in patients with NSCLC remains to be defined.

1.2.2. The PI3-Kinase/Akt pathway in NSCLC
In addition to the Ras/MAPK pathway, the PI3-Kinase pathway represents another
major signaling network downstream of EGFR activation. PI3-Kinases have been linked
to an extraordinarily diverse group of cellular functions, including cell growth,
proliferation, differentiation, motility, survival and intracellular trafficking56-59. Although
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three classes of PI3-Kinases exist (classes I, II, III) and signaling through all classes are
connected to key growth-regulatory processes, thus far a central role in cancer has been
demonstrated selectively for class IA PI3-Kinases. Therefore, the discussion will focus on
signaling through class IA PI3-Kinases.
The PI3-Kinase/Akt pathway is a central regulator of cell proliferation and survival
and is dysregulated by oncogenic events in a substantial fraction of malignant tumors. It is
targeted by genomic abnormalities including mutation, amplification and rearrangement
more frequently than any other pathway in human cancer, with the possible exception of
the p53 and retinoblastoma (Rb) pathways. A clear link between the PI3-Kinase pathway
and cancer was initially established in the 1980s when two viral oncoproteins, the src
protein of Rous sarcoma virus and the middle-T protein of polyma virus, were associated
with the pathway‘s lipid kinase activity60,61. Binding of the p85 subunit of PI3-Kinase to
phospho-tyrosines on the viral oncoproteins leads to the recruitment of the p110α catalytic
subunit, thereby activating the PI3-Kinase signaling pathway. Since then, it has been
demonstrated that PI3KCA (the gene encoding the p110α subunit of PI3-Kinase) and
PTEN are two of the most frequently mutated genes in human cancers resulting in
deregulated activation of PI3-Kinase signaling.

Specifically, PI3KCA is frequently

amplified or mutated in head and neck, cervical, gastric, ovarian, breast, and lung
cancers62-68.
Recently, it has been demonstrated that Akt, the critical downstream effector of
PI3K, is constitutively active in most NSCLC cell lines and in 51% of NSCLC patient
samples69,70. Similar work has also revealed Akt as a crucial mediator of NSCLC cell
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survival and therapeutic resistance69,71. Additionally, studies have shown that high levels
of phosphorylated Akt in NSCLC are a marker for a poor prognosis72. These studies
provide evidence for a central role of PI3-Kinase/Akt in tumorigenesis.

1.2.3. Signaling through the PI3-Kinase/Akt pathway
Genetic studies in Caenorhabditis elegans and Drosophila melanogaster have
enlightened our understanding of PI3-Kinase regulation. PI3-Kinase can be activated in
response to the binding of growth factors to their respective receptor protein tyrosine
kinases (RTKs). RTKs include epidermal growth factor receptor (EGFR), platelet-derived
growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR),
fibroblast growth factor receptor (FGFR), as well as many others. In response to growth
factors, RTKs interact with the p85 regulatory subunit of PI3-Kinase and localize it to the
plasma membrane. Upon activation, PI3-Kinase phosphorylates PI(4,5)P2 to generate the
lipid second messenger PI(3,4,5)P3. The lipid phosphatase PTEN antagonizes PI3-Kinase
signaling by dephosphorylating PI(3,4,5)P3 into PI(4,5)P2, thus acting as the central
negative regulator of the pathway. PI(3,4,5)P3 is now available to recruit and bind a subset
of proteins containing pleckstrin-homology (PH) domains. These proteins include Akt
(PKB), Tec family tyrosine kinases, guanine nucleotide exchange factors (GEFs) for Rac,
and GTPase-activating proteins (GAPs). However, genetic screens in model organisms
have identified Akt as the primary downstream mediator of the effects of PI3-Kinase.
Akt, or protein kinase B, is a critical downstream effector of PI3-Kinase and is
located at a crucial crossroads of various signaling events. In humans, there are three
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isoforms of Akt which are produced from three separate genes: Akt1, Akt2, and Akt3. The
N-terminal region of Akt harbors the PH domain, which is recruited to and interacts with
PI(3,4,5)P3 at the plasma membrane. Recruitment of Akt to the membrane induces a
conformational change, exposing two crucial amino acids that are phosphorylated and
necessary for activation. Threonine 308 is located in the kinase domain of Akt and is
phosphorylated by active phosphoinositide-dependent kinase 1 (PDK1).

This

phosphorylation event stabilizes the activation loop whereas phosphorylation of serine 473
in the hydrophobic C-terminal domain by PDK2 is necessary for full Akt activation73,74.
The identity of PDK2 is still unknown. However, recent reports have proposed several
different possibilities, including the mTOR rictor complex (separate from the mTOR raptor
complex inhibited by rapamycin), integrin-linked kinase (ILK), PKCβII and even AKT
itself, thereby allowing the pathway potential for feedback control75-77.
The PI3-Kinase/Akt pathway is a key regulator of cell survival through multiple
downstream targets78-80. It has been clearly demonstrated that Akt can function to enhance
cell proliferation and survival through inhibition of the forkhead (FOXO) family of
transcription factors, including AFX, FKHR, and FKHRL1.

These transcription factors

are known to mediate apoptosis by activating transcription of FasL and Bim, two well
documented pro-apoptotic genes81. However, Phosphorylation of the FOXO proteins by
Akt forces their retention in the cytoplasm through interactions with 14-3-3 proteins,
thereby sequestering them from activating transcription of their gene targets. Similarly,
Akt can phosphorylate the proapoptotic Bcl-2 family member Bad, preventing its
translocation to the mitochondrial membrane through interactions with 14-3-3 proteins82.
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Additionally, reports have demonstrated that, under certain conditions, Akt can act to
promote cell survival by phosphorylating I-θB kinase, which activates the pro-survival
transcription factor nuclear factor-θB (NF-θB)83,84.

1.2.4. The PLCγ/PKC pathway in NSCLC
A final key pathway involved in activation of EGFR involves activation of
phospholipase C-γ (PLCγ). Four PLC subfamilies have been identified, with PLCγ being
the only isoform known to be downstream of receptor tyrosine kinases (RTKs), such as
EGFR. Activation of PLCγ results in hydrolyzation of PI(4,5)P2 to generate inositol-3phosphate (IP3) and diacylglycerol (DAG), allowing for subsequent release of calcium
ions from intracellular stores and activation of Protein Kinase C85.
Protein kinase C (PKC) is a family of ubiquitously expressed, phospholipiddependent enzymes involved in signal transduction associated with cell proliferation,
differentiation, and apoptosis86. It is now well established that the PKC is a family of at
least 12 serine threonine kinases87. Each PKC isozyme differs in structure, biochemical
properties, tissue distribution, subcellular localization, and substrate specificity. The
mammalian PKCs are classified on the basis of their enzymatic properties as either
classical, novel, or atypical. The classical PKCs (α, βI, βII, γ) are Ca2+-dependent and are
activated by diaclyglycerol (DAG). The novel PKCs (δ, ε, ζ, ε) are Ca2+-independent and
are activated by DAG. Lastly, the atypical PKCs (η, δ) do not require Ca2+ for their
activation nor are activated by DAG.
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PKCs have been demonstrated to act as key cellular components in major signaling
pathways involving Ras, Myc, and Fos88 and altered PKC activity has been linked with
various types of malignancies. Higher levels of PKC and differential activation of various
PKC isozymes have been reported in breast, renal, pancreatic, and colon cancers89-91.
Several studies have also presented evidence that overexpression of different PKC
isoforms induces cell proliferation and enhanced tumorigenicity. For example, fibroblasts
overexpressing PKCβI, PKCε, and PKCγ resulted in an increased proliferation rate,
anchorage-independent growth, and enhanced tumorigenicity in nude mice92-95.
Furthermore, the overexpression of PKCα in MCF-7 breast cancer cells led to a more
aggressive neoplastic phenotype96. However, there are a number of conflicting reports on
whether overexpression of PKC increases or suppresses tumorigenicity in various cells97,98.
For example, colon carcinoma cells overexpressing PKCβI resulted in tumor growth
inhibition99. These observations have led researchers to believe that each PKC isozyme
plays critical, yet differing roles in tumorigenesis.
The role of PKC isozymes in cancer have been studied for the past 20 years.
However, it was only in 2005 that the first PKC isozyme, PKCη, was demonstrated to be a
human oncogene100. PKCη is at the hub of several major oncogenic signaling pathways
and has been directly implicated in Ras-mediated siganaling101,102. Overexpression of PKCη
is found in NSCLC cell lines and primary tumors, and correlates with poor clinical
outcome in NSCLC patients100. However, the related atypical PKC, PKCδ, is expressed at
low levels in malignant lung tissue indicating PKCη is selectively targeted in
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oncogenesis103. These data provide a rationale for PKCη-targeted therapy in the treatment
of lung cancer.

1.3. RNA Splicing
In cancer, the control of alternative RNA splicing can be dysregulated as a
consequence of alterations within signaling cascades, such as the PI3-Kinase/Akt
pathway104. RNA splicing is the process by which introns, or intervening sequences within
protein-coding genes, are removed from unprocessed RNA (pre-mRNA) to produce
―mature messenger RNA‖ (mRNA) prior to translation into protein. A central regulatory
mechanism in mammalian cells is the alternative splicing of pre-mRNA in which multiple
mRNA transcripts are generated from a single mRNA precursor. Research on the human
genome has demonstrated that alternative splicing is an important mechanism responsible
for regulating a multitude of biological processes via production of variant protein
products, therefore playing a role in a wide range of human diseases. The following
sections will discuss the current understanding of pre-mRNA splicing and the mechanisms
that regulate mammalian pre-mRNA splicing. It also will discuss the role of alternative
splicing in lung cancer.

1.3.1. Pre-mRNA splicing
In the late 1970s, the laboratories of Phillip Sharp and Richard Roberts both
independently discovered that genes are not continuous strings but contain non-coding
regions of DNA, later termed introns. Furthermore, deletion of these introns through
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splicing of pre-mRNA can occur in multiple ways, yielding different protein isoforms from
the same DNA sequence105,106. Along with 5′ capping and 3′ polyadenylation, RNA
splicing is a critical post-transcriptional processing step.
The removal of introns from pre-mRNA, and subsequent joining of exons, is
governed by the recognition of sequences at the intron/exon junctions known as splice
sites. The exon/intron junction at the 5‘ end of the intron marks the 5‘ splice site and
includes a GU dinucleotide surrounded by a less conserved consensus sequence. The 3‘
splice site is located at the opposite end of the same intron and contains three conserved
sequence elements: the branch point, followed by a polypyrimidine tract, followed by an
intronic terminal AG dinucleotide. A two-step transesterification reaction removes the
unnecessary introns. In the first step, the 2‘ hydroxyl group of the branch site adenosine
attacks the phosphate at the 5‘ splice site of the intron, leading to reaction intermediates:
the 5‘ exon and an intron/3‘ exon lariat. In the second step, the free 3‘-hydroxyl of the 5‘
exon attacks the phosphate at the 3‘ end of the intron. This results in release of the inton,
still in lariat form, and ligation of the two flanking exons.
The splicing reaction is catalyzed by the spliceosome, a macromolecular complex
consisting of five small nuclear ribonucleoprotein particles (U snRNPs) and over 150 nonsnRNP splicing factors107. Each snRNP is a complex containing a short RNA molecule
(U1, U2, U4, U5, and U6 snRNAs) and Sm (or Sm-like) proteins, along with several other
specific proteins108. Formation of the spliceosome involves an ordered, stepwise assembly,
during which complexes E, A, B, and C are formed on the pre-mRNA109. Formation of the
early (E) complex occurs following U1 snRNP binding to the 5‘end splice site, binding of
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splicing factor 1 (SF1) to the branch site, and recognition of the 3‘ splice site by U2 snRNP
auxiliary factor (U2AF)110,111. This commitment complex is independent of ATP and
commits the pre-mRNA to splicing. U2 snRNP interacts with U2AF at the branch site in
an ATP-dependent reaction forming the pre-spliceosome complex A.

Next, the pre-

assembled U4/U5/U6 tri-snRNP is recruited to form Complex B. Following extensive
structural and compositional rearrangements, Complex B becomes catalytically
activated112. The catalytic core of the spliceosome is formed on pre-mRNA by U2, U5,
and U6 snRNPs. Both steps of the splicing reaction (described above) are catalyzed in the
activated complex B and complex C. Lastly, Spliceosome disassembly is initiated by the
release of the newly spliced mRNA and lariat intron.

1.3.2. Mechanisms of Alternative spicing
Alternative splicing occurs as a normal phenomenon and is a major source of
protein diversity from the human genome. Through the process of alternative splicing,
multiple mRNAs are produced from a single pre-mRNA which encodes structurally and
functionally different proteins. Initial estimates suggested that only a small number of
genes underwent alternative splicing113.

However, current research using large-scale

oligonucleotide-based microarrays now suggests that at least 70%-80% of human genes
have splice variants114,115.
In the typical pre-mRNA, the splicing pattern can be modified in a variety of ways
depending on splice site selection. In addition to the splice signals flanking the exon/intron
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junctions (i.e. the 5‘splice site, branch site, polypyrimidine tract, and the 3‘splice site),
other auxiliary signals have recently been identified as playing an important role in
repressing or enhancing splice site selection.

These elements are short, conserved

sequences and are classified according to their location and function. Splicing silencers are
regions on the pre-mRNA to which splicing repressor proteins bind, reducing the
probability that a nearby site will be used as a splice site. Splicing silencers can be located
in an intron (intronic splicing silencer, ISS) or a neighboring exon (exonic splicing
silencers, ESS). Splicing enhancers are regions of the pre-mRNA to which splicing
activator proteins bind, increasing the probability that a nearby site will be used as a splice
site. Like splicing silencers, enhancers may also occur in introns (intronic splicing
enhancers, ISE) or exons (exonic splicing enhancers, ESE). In the majority of cases,
splicing silencers and enhancers exert their effects through the binding of regulatory
proteins, most notably members of the serine-arginine-rich (SR) protein family116 and
members of the heterogenous nuclear ribonucleoproteins (hnRNP) family117.

1.3.3. SR proteins
Serine/arginine-rich (SR) proteins are a family of highly conserved splicing factors
with functions in both constitutive and alternative pre-mRNA splicing118-123. SR proteins
contain a characteristic RS domain rich in arginine and serine dipeptide repeats, and one or
two RNA recognition motifs (RRMs). The RRM provides RNA-binding specificity
whereas the C-terminal RS domain promotes protein-protein interactions that facilitate
spliceosomal assembly124,125. More recently, studies have shown that the RS domain can
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also function as a nuclear localization signal (NLS) by mediating the interaction with the
SR protein nuclear import receptor, transportin-SR126-128. In humans, the ‗classical‘ SR
protein family members are defined based on the following criteria: (i) structural
similarity, (ii) dual function in constitutive and alternative splicing, (iii) precipitate in the
presence of 20mM MgCl2, and (iv) the presence of a conserved phosphoepitope within the
RS domain and recognized by mAb104. Additional RS domain-containing proteins exist
but lack one or more of the requirements of a ‗classical‘ SR protein.
SR proteins are primarily localized within nuclear speckles. However, studies have
demonstrated that their subcellular localization can be modified by the phosphorylation
status of the RS domain129-131.

The serine residues in the RS domain are extensively

phosphorylated and, in addition to subcellular localization, the phosphorylation status can
also regulate protein-protein interactions132,133, both of which may regulate the ability of
SR proteins to function in splicing. In fact, both hyper- and hypo-phosphorylated SR
proteins are unable to support splicing134-136.
Three protein kinases are widely accepted as directly phosphorylating the RS
domains of SR proteins. These include the SR protein kinase family SRPK1137 and
SRPK2132, the Clk/Sty family138, and DNA topoisomerase 1139. Experiments performed in
D. melanogaster have provided the most direct evidence for an in vivo role of SR protein
kinases. DOA is the homolog of Clk/Sty found in Drosophila. DOA phosphorylates the
Drosophila SR protein RBP1 as well as Tra and Tra2140.

It was demonstrated that

mutations in Doa disrupt the splicing of doublesex pre-mRNA, but have no effect on the

22
splicing of fruitless pre-mRNA – both regulated by RBP1, Tra, and Tra2140. Interestingly,
these SR proteins control alternative 3‘ splice site selection in doublesex pre-mRNA and
alternative 5‘ splice site selection in fruitless pre-mRNA, suggesting that 5‘ and 3‘ splice
sites regulated by SR proteins have different requirements for RS domain
phoshorylation140.
Recently the PI3-Kinase/Akt pathway has been suggested to alter the activity of SR
proteins.

Specifically, Srebrow and colleagues have provided evidence for a direct

involvement of Akt in modifying the activity of the SR proteins, SRp30a and 9G8141.
Independent of this study, Akt was also demonstrated to phosphorylate SRp40 and modify
the alternative splicing of PKCβII142.
Due to their critical roles as essential splicing factors and as splicing regulators,
disruption of SR proteins can lead to human disease. It has been reported that 15% of
mutations that result in genetic disease affect pre-mRNA splicing143, disrupting 5‘ splice
sites, 3‘ splice sites, enhancer sequences, and silencer sequences.

Recent analyses

demonstrate that more than 50% of single-base substitutions associated with exon-skipping
disrupted at least one of the target motifs for the SR proteins SRp30a, SRp40, SRp55 and
SC35144,145. Recent reports have also established a link between the mis-expression of SR
proteins and cancer.

Specifically, SRp30a, SC35, and SRp20 were found to be

overexpressed in malignant ovarian tissue146 and SRp30a upregulated in lung, colon,
kidney, liver, pancreatic, and breast tumors147. These data suggest that SR proteins play a
role in cancer development.
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1.4. Apoptosis
Apoptosis is a tightly regulated execution of signaling pathways leading to the
removal of cells. In 1970, John Foxton Ross Kerr at University of Queensland was able to
identify and distinguish apoptosis (Greek: apo - from, ptosis - falling) from traumatic cell
death, known as necrosis. The end result of apoptosis, as opposed to necrosis, is cell death
without inflammation of the surrounding tissue. Apoptosis is characterized by a variety of
morphological changes, including changes to the cell membrane such as loss of membrane
asymmetry and attachment, cell shrinkage, nuclear fragmentation, chromatin condensation,
and chromosomal DNA fragmentation148-150. Apoptosis plays a crucial role in developing
and maintaining health by eliminating old, unnecessary, or unhealthy cells. In fact, defects
in apoptotic pathways are now thought to contribute to a number of human diseases,
ranging from neurodegenerative disorders to malignancy.
In mammalian cells, apoptosis occurs via two main signaling pathways.

The

―extrinsic‖ or receptor-mediated pathway, is triggered when pro-apoptotic ligands bind to
pro-apoptotic receptors on the cell surface. In contrast, the ―intrinsic‖ or mitochondrial
pathway is initiated from within the cell as a result of cellular developmental cues or
significant cellular stress (e.g., DNA damage), and when stimulated leads to the release of
cytochrome c from the mitochondria and activation of the death signal. Both pathways
converge to a final common pathway in which the destruction of the cell is ultimately
carried out by caspases - intracellular protease enzymes that, upon activation, destroy
cellular proteins vital for cell survival and stimulate fragmentation of chromosomal DNA.
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1.4.1. Extrinsic Pathway
The extrinsic pathway is triggered in response to external pro-apoptotic ligands,
such as endogenous Apo2L/TRAIL and CD95L/FasL. Binding of these ligands to their
pro-apoptotic cell surface receptors DR4/DR5 and CD95/Fas, respectively, may lead to
apoptosis. Unlike the intrinsic pathway, the extrinsic pathway triggers apoptosis
independently of the p53 protein.

When a death stimulus triggers the pathway, the

membrane-bound FasL interacts with adaptor protein Fas-associated death domain
(FADD) and initiator caspases 8 or 10 as procaspases, forming the death-inducing
signaling complex (DISC). Formation of DISC facilitates the autocatalytic processing and
release of caspase 8 into the cytoplasm where it, in turn, activates caspases 3, 6, and/or 7.
Upon DISC activation, the extrinsic pathway converges with the intrinsic pathway and
adopts the same effector caspase machinery.
Several pathways and proteins regulate the activation of the extrinsic pathway. cFLICE inhibitory protein (c-FLIP) acts to inhibit DISC formation by interacting with
FADD to block initiator caspase activation. Other inhibitors of the pathway include FAP-1
and the soluble decoy receptors such as DcR3, TRAIL R-3/DcR1, and TRAIL R-4/DcR2
which can act to block FasL binding and Fas receptor stimulation.

1.4.2. Intrinsic pathway
As its name suggests, the intrinsic pathway is initiated from within the cell, usually
in response to cellular signals resulting from DNA damage, a defective cell cycle,
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detachment from the extracellular matrix, hypoxia, or loss of cell survival factors. When
stimulated, the intrinsic pathway, leads to the release of cytochrome c from the
mitochondria and activation of caspases. This process ultimately triggers apoptosis151-154.
One of the most important regulators of the intrinsic pathway is the members of the
Bcl-2 superfamily of proteins, which act to regulate the permeability of the mitochondrial
membrane152. The Bcl-2 family includes pro-apoptotic members such as Bax, Bak, Bad,
Bcl-Xs, Bid, Bik, Bim, and Hrk, and antiapoptotic members such as Bcl-2, Bcl-x(L), BclW, Bfl-1, and Mcl-1.

Members of the Bcl-2 family contain signature domains of

homology called Bcl-2 homology (BH) domains (termed BH1, BH2, BH3, and BH4)155.
Pro-apoptotic Bcl-2 members act as promoters of apoptosis by allowing permeabilization
of the mitochondrial membrane. In contrast, anti-apoptotic Bcl-2 members function to
repress apoptosis by acting to prevent permeabilization of the mitochondrial membrane
and blocking cytochrome-c release.
Once the mitochondrial membrane becomes permeable (triggered by apoptotic
stimuli), cytochrome-c, second mitochondria-derived activator of caspase (also known as
direct IAP-binding protein), and the pro-apoptotic protein SMAC/DIABLO are released
into the cytosol. SMAC/DIABLO protein promotes apoptosis by directly interacting with
inhibitors of apoptosis proteins (IAPs) and disrupting their ability to inactivate the caspase
enzymes. Cytochrome-c is now able to interact with adaptor apoptotic protease activating
factor-1 (Apaf-1) and (d)ATP, forming a large multiprotein structure known as the
apoptosome. The apoptosome is assembled when seven Apaf-1:cytochrome c heterodimers
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oligomerize to form a symmetrical "wheel" and procaspase-9 molecules become associated
non-covalently
interaction156,157.

to
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The primary function of the apoptosome is theorized to be

multimerization and allosteric regulation of the catalytic activity of caspase 9. Initiator
caspase 9 is recruited into the apoptosome and activated, which in turn initiates the caspase
cascade involving effector caspases 3, 6, and/or 7158.

1.4.3. Caspase 9
The caspase cascade plays a vital role in the induction, amplification, and execution
of apoptotic signals within the cell. The caspases, or cysteine-aspartic acid proteases, are a
family of intracellular proteases that — upon activation through the intrinsic and/or
extrinsic pathways — destroy essential cellular proteins, leading to apoptosis. Robert
Horvitz initially established the importance of caspases in apoptosis through his discovery
of the ced-3 gene and its requirement for cell death in the development of nematode C.
elegans. Horvitz and his colleague Junying Yuan found in 1993 that the protein encoded
by the ced-3 gene was cysteine protease, now known as caspase 1159. Since then, eleven
caspases have been identified in humans and are classified as either initiator (apical)
caspases or effector (executioner) caspases.
Initiator caspases (caspases 2, 8, 9, and 10) are activated through either the intrinsic
or extrinsic apoptosis-signaling pathways and are responsible for the activation of the
effector caspases (caspases 3, 6, and 7) which, in an expanding cascade, carry out
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apoptosis153,160. The effector caspases induce cleavage of protein kinases, cytoskeletal
proteins, DNA repair proteins, and ultimately destroy ―housekeeping‖ cellular functions,
leading to the morphologic expression of apoptosis.
At cytosolic concentration in human cells (<50 nM), procaspase-9 is monomeric
and resides as a zymogen161,162. In contrast to executioner caspases, caspase 9 does not
require proteolysis in the linker region to become active161,163-166. Instead, caspase 9 is
activated by small-scale rearrangements of its active site162. Currently, two opposing
theories exist in regards to the mechanism of caspase 9 activation; the allosteric model and
the proximity-induced model. In the allosteric model, a single monomer of caspase 9
interacts with the apoptosome; an interaction which induces rearrangements of the active
site. In contrast the induced proximity model suggests that as the local concentration of
caspase 9 increases, a kinetic barrier is overcome to induce dimerization and
monomer/monomer contacts within the catalytic domain of the caspase-9 dimer cause the
activating rearrangements.
In 1999, two groups independently identified an alternatively splice variant of
caspase 9, termed caspase 9b, which acts as a dominant-negative inhibitor of caspase 9
activation167,168. Sequence analysis revealed that the caspase 9b splice variant lacked the
exon 3,4,5,6 cassette (residues 140-289) encoding the catalytic domain of caspase 9.
Further studies demonstrated caspase 9b antagonized caspase 9a activity by 1) competing
with caspase 9a for Apaf-1 binding and/or 2) caspse 9b binds with caspase 9a and blocks
its auto-proteolysis167,168.

These results suggest that caspase-9b functions as an
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endogenous apoptosis inhibitory molecule by interfering with the formation of a functional
Apaf-1-caspase-9 complex.
Additional findings by Alnemeri and colleagues illustrated that the ratio of caspase
9a to caspase 9b can greatly influence a cell‘s decision to undergo apoptosis. In these
studies, MCF-7 cells transiently transfected with caspase 9b were significantly desensitized
to apoptotic stimuli168. Consistent with these findings, Weller and colleagues demonstrated
transient overexpression of caspase 9b protected LN-229 astrocytoma cells from Fasmediated apoptosis169. The above findings suggest caspase 9b can negatively regulate
apoptosis by a dominant-negative mechanism. Therefore, regulation of the inclusion of this
four exon cassette is a possible critical determinant to decide whether a cell is susceptible
or resistant to apoptosis.
Numerous studies in the literature demonstrate a role for caspase 9 in both the
response of cells to undergo chemotherapy-induced cell death and the suppression of
oncogenic transformation167,168,170-178. As to the latter, Lowe and co-workers demonstrated
that p53 null cells as well as caspase 9 -/- cells were resistant to apoptosis induced by cMyc and oncogenic Ras (h-RasV12) expression

179

.

Furthermore, mouse embryonic

fibroblasts cells devoid of either caspase 9 or p53 demonstrated dramatic enhancement of
cellular transformation by c-Myc and oncogenic Ras as assayed by colony formation in
soft agar and tumorigenesis in nude mice

179

. Studies to orient the pathway by the same

laboratory group also demonstrated that caspase 9 was downstream of p53 in this pathway
179

. Thus, caspase 9 acts as a tumor suppressor of c-Myc and H-RasV12 transformation by

playing a major role in the p53-dependent pathway of apoptosis/senescence 179.
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1.4.4. Bcl-x
In 1993 Boise, L.H. et al. indentified and characterized a Bcl-2 related gene, Bcl-x,
which functions independently of Bcl-2 in regulating apoptosis.

This report indentified

two distinct isoforms of the gene, termed Bcl-x(L) and Bcl-x(s). Bcl-x(L), the larger of the
two isoforms, was demonstrated to serve as an inhibitor of apoptosis whereas Bcl-x(s)
possesses an antagonistic function, to promote apoptosis.

Specifically Bcl-x(s) was

demonstrated to inhibit the ability of Bcl-2 to promote apoptosis180. Additional studies
revealed that Bcl-x(L) and Bcl-x(s) are both generated from the Bcl-x gene via alternative
splicing of two distinct 5‘ splice sites located within exon 2 of the Bcl-x pre-mRNA
transcript180. Processing at the upstream (intron distal) 5' splice site results in processing of
the smaller (170 amino acids) Bcl-x(s) isoform, while processing at the downstream (intron
proximal) 5' splice site results in processing of the larger (233 amino acids) Bcl-x(L). Bclx(L) contains an additional 63 amino acids, encoding for two Bcl-2 homology domains,
BH1 and BH2 that are lacking in Bcl-x(s)181. The presence and absence of the BH1 and
BH2 domains is responsible for the antagonizing functions of Bcl-x(L) and Bcl-x(s)181.
Research has demonstrated that mutations in either BH1 or BH2 domain of Bcl-x(L)
compromise its ability to interact with other Bcl-2 family members, such as Bad and Bax,
and prevent it from carrying out its anti-apoptotic functions182,183.
The antagonistic behaviors of Bcl-x(L) and Bcl-x(s) have been demonstrated to
influence the regulation of apoptotic signaling. Numerous studies have shown that
overexpression of Bcl-x(L) in cells confers resistance to many apoptotic stimuli, and
cooperates with oncogenic factors (e.g. c-Myc) in tumorigenesis180,181,184-191. Furthermore,

30
many cell types spontaneously resistant to chemotherapeutic agents also demonstrate
increased levels of Bcl-x(L)192-197. The regulation of Bcl-x(L) expression is a complex
mechanism consisting of both transcriptional and post-transcriptional processes. Several
studies have demonstrated that the Bcl-x splice variant, Bcl-x(s), in contrast to Bcl-x(L),
promotes apoptosis181,198-201, and the mechanism of alternative 5‘ splice site selection of
Bcl-x pre-mRNA has emerged as a potential target for anti-cancer therapeutics in nonsmall cell lung cancer (NSCLC).

CHAPTER 2
THE PI3-KINASE/AKT PATHWAY REGULATES THE ALTERNATIVE
SPLICING OF CASPASE 9 IN A PRO-ONCOGENIC MANNER.

2.1. Introduction
Regulation of pre-mRNA splicing plays an important role in human disease202.
Although a major source of cancer-causing errors in gene expression arise from mutations
in enhancer or silencer elements located in pre-mRNA, research over the past two decades
have reported cancer-specific alternative splicing in the absence of genomic mutations.
For example, the alternatively spliced variant of MDM2 oncoprotein, MDM2b, is unable to
bind p53 due to the exclusion of the p53-binding domain. MDM2b PCR products were
exclusively detected in osteosarcomas and not normal bone and their levels overexpressed
in astrocytomas, ovarian cancers, and bladder cancers203-205.
In order to influence the development and progression of cancer, the alternatively
spliced variant must likely be expressed in significant amounts in relation to its
predominantly spliced variant. Unpublished reports from our laboratory demonstrate that a
46% reduction in the caspase 9a/9b mRNA ratio corresponds to a 62% reduction in
caspase 9 activity. Conversely, a two-fold increase in the caspase 9a/9b mRNA ratio
corresponds to a 2.7-fold increase in the caspase 9 activity. Thus, modulation of the
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alternative splicing of caspase 9 could greatly influence the cell‘s decision to undergo
apoptosis.
Caspase 9 is a critical regulator in the apoptotic pathway and its activation is
required for cell death induced by various chemotherapies, stress agents, and
radiation167,168,170-176. Research published by Soengas et al. in 1999 revealed that caspase 9
(caspase 9a) plays a distinct role in oncogenesis, acting as a tumor suppressor179.
Specifically, caspase 9 was shown to act downstream of p53 and have a profound effect on
suppressing the tumorigenicity of MEFs expressing oncogenic ras (h-RasV12) and cMyc179.

The data presented demonstrates that knockout of caspase 9a can facilitate

oncogenic transformation and tumor development.
In 1999, a novel isoform of caspase 9 was cloned from human liver cDNA, termed
caspase-9S167. In the same year, an independent study by Srinivasula et al. also identified
the transcriptional variant of caspase 9, designating it caspase 9b168.

Both reports

demonstrated that caspase 9b functions as an endogenous dominant-negative isoform of
the full-length caspase 9, acting to inhibit recruitment and activation of procaspase 9167,168.
In addition, Seol and Billiar were the first to demonstrate that the alternative spliced
caspase 9 isoform, caspase 9b, is expressed in significant levels in various cancer cell
lines167. In this study, we tested the hypothesis that the alternative splicing of caspase 9
was dysregulated in a pro-survival manner (lower caspase 9a/9b mRNA ratio) in NSCLC
patient tumor samples consisting of adenocarcinoma, squamous cell carcinoma, and large
cell carcinoma histologies. Additionally, we hypothesize that one of the major mitogenic
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signaling pathways regulates the alternative splicing of caspase 9 to favor the production of
caspase 9b, thereby decreasing the caspase 9a/9b mRNA ratio.

2.2. Materials and Methods
2.2.1. Cell Culture
A549, H2347, H358, H226, H2170, H596, H1792, H1299, H520, H1703 and H292
cells were grown in 50% RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) and
50% Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Carlsbad, CA)
supplemented with L-glutamine, 10% (v/v) fetal bovine serum (Sigma), 100 units/ml
penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). H2030 and H838 cells
were grown in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Sigma), 100
units/ml penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). All adenocarcinoma
and squamous carcinoma cell lines were purchased from ATCC (Rockville, MD, USA).
HBEC-3KT cells, a generous gift from J.D. Minna, were cultured with keratinocyte serumfree medium containing 50μg/ml bovine pituitary extract and 5ng/ml recombinant
epidermal growth factor (Life Technologies, Gaithersburg, MD). NHBE cells, purchased
from Clonetics (Cambrex Bio Science, Lonza Group Ltd, Switzerland) were maintained in
basal bronchial epithelial growth media (BEGM) supplemented with SingleQuot Kitsgrowth factors, cytokines and supplements (Cambrex, Lonza, Lonza Group Ltd,
Switzerland). All cells were maintained at less than 80% confluency under standard
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incubator conditions (humidified atmosphere, 95% air, 5% CO2, 37 °C). For all
comparison studies between cell lines, 1.2 x 105 cells were plated in tissue culture plates (6
well dish). The following day, media was removed, cells were washed with 1 x PBS and
plated in keratinocyte serum-free medium without supplements overnight. Total RNA
and/or protein was then isolated for analysis.

2.2.2. Quantitative/Competitive RT-PCR
Total RNA from cell lines were isolated using the RNeasy® Mini Kit (Qiagen Inc.,
Valencia, CA) according to the manufacturer‘s protocol. Total RNA (1 μg) was reversetranscribed using Superscript III reverse transcriptase (SuperScript™ First-Strand
Synthesis System for RT-PCR, Invitrogen™, Carlsbad, CA) and oligo (dT) as the priming
agent. After 50 min of incubation at 42°C, the reactions were terminated by heating at
70°C for 15 min. Template RNA was then removed using RNase H (Invitrogen, Carlsbad,
CA). To quantitatively evaluate the expression of endogenous caspase 9 splice variants, an
upstream 5‘ primer to caspase-9 (5‘-GCT CTT CCT TTG TTC ATC TCC-3‘) and a 3‘
primer (5‘-CAT CTG GCT CGG GGT TAC TGC-3‘) (Integrated DNA Technologies, Inc.,
Coralville, IA) were used. Using these primers, 20% of the reverse transcriptase reaction
was amplified for 25 cycles (94°C, 30 s melt; 57°C, 30 s anneal; 72°C, 1 min extension)
using Platinum Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA). Gene
products produced from endogenous caspase 9 PCR resulted in a 1248 base pair caspase 9a
splice variant and 798 base pair caspase 9b splice variant. The primers used to evaluate
caspase 8 splice variants are sense (5‘-GCA TTA GGG ACA GGA ATG GA-3‘) and
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antisense (5‘-GAA GGG GAC TTC AAA CCA GTG-3‘).

The PCR conditions for

caspase 8 were 95ºC for 5 mins followed by 25 cycles of 94ºC for 30s, 60ºC for 30s and
72ºC for 1min. The primers used to evaluate caspase 2 splice variants are sense (5‘-ACT
TGC TGC CTA AGA GGG GTC- 3‘) and antisense (5‘-CTT GGG CAG TTG GCG TTG
TC -3‘). The PCR conditions for caspase 2 were 95ºC for 5 mins followed by 25 cycles of
94ºC for 30s, 64ºC for 30s and 72ºC for 1min. The primers used to evaluate Bcl-x splice
variant were (5‘-GAG GCA GGC GAC GAG TTT GAA-3‘) and (5‘-TGG GAG GGT
AGA GTG GAT GGT-3‘). The PCR conditions for analyzing the expression of Bcl-x
splice variants were 95ºC for 5 mins followed by 25 cycles of 94ºC for 30s, 58ºC for 30s
and 72ºC for 1min. The final PCR products were resolved on a 5% TBE acrylamide gel
electrophoresis, stained with SYBR® Gold (Invitrogen™, Carlsbad, CA) and visualized
using a Molecular Imager® FX (Bio-Rad) with a 488 nm EX (530 nm BYPASS) laser.

2.2.3. Western Immunoblotting
Cells were lysed using CelLytic™ lysis Buffer (Sigma-Aldrich) supplemented with
protease Inhibitor cocktail (Sigma-Aldrich). Protein samples (5 μg) were subjected to 10%
SDS-PAGE, transferred to a polyvinylidene difluoride membrane (PDVF) (Bio-Rad) and
blocked in 5% milk/1 X PBS – 0.1% Tween (M-PBS-T) for 2 h. Primary antibodies were
anti-caspase 9 (1:1,000, Assay Designs), anti-Akt1 (1:1,000, Santa Cruz), anti-Akt2
(1:1,000, Santa Cruz), anti-PDK-1 (1:1,000, Santa Cruz), anti-T7 tag (1:10,000, Novagen),
and anti-β-actin (1:5,000, Sigma-Aldrich). Secondary antibodies were HRP-conjugated
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goat anti-mouse or anti-rabbit (1:5,000, Sigma-Aldrich). Immunoblots were developed
using Pierce enhanced chemiluminescence (ECL) reagents and Bio-Max film.

2.2.4. Inhibitor studies and adenoviral infection
For Inhibitor studies, 1.2 x 105 cells were plated into 6-well tissue culture plates.
The following day media was removed and replaced with the appropriate complete growth
media. Cells were subsequently treated with sham control (1:1000) or the appropriate
concentration of active inhibitor (1:1000) (Calbiochem). Twenty-four hours posttreatment, total RNA and/or protein was isolated. For adenoviral infection, 1.2 x 105 cells
were plated into 6-well tissue culture plates. Two hours later, cells were infected with
either constitutively active AKT2 adenovirus, PTEN adenovirus, or Null adenovirus
(50MOI) (Vector Biolabs). Forty-eight hours later, total RNA and/or protein was isolated.

2.2.5. Silence interfering RNA transfection
For inhibition of Akt1, Akt2, and PDK-1 expression, cell lines were transfected
with either Akt1 SMARTpool multiplex, Akt2 SMARTpool multiplex, PDK-1
SMARTpool multiplex or scrambled control siRNA (Dharmacon; Lafayette, CO) using
Dharmafect 1 transfection reagent (Dharmacon; Lafayette, CO) following the
manufacturer‘s protocol. Briefly, cell lines were plated in six-well tissue culture dishes and
allowed to rest overnight. At 50% confluence, cells were transfected with siRNA [100nM]
using Dharmafect 1 in Opti-Mem I reduced-serum medium.
transfection, RNA and/or protein were isolated.

Forty-eight hours post-
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2.3. Results
2.3.1. The alternative splicing of caspase 9 is dysregulated in a variety of NSCLC
tumors and transformed lung cancer cells.
In this study, we examined the hypothesis that the alternative splicing of caspase 9
was dysregulated (in a pro-survival manner (e.g. lower C9a/C9b mRNA ratio)) in NSCLC
tumors, including adenocarcinomas, squamous cell carcinomas, and large cell carcinomas.
Utilizing total RNA from pathologist-verified human NSCLC tumor samples,
quantitative/competitive RT-PCR analysis was performed to determine the degree of
dysregulation in the caspase 9a/9b mRNA ratio as compared to matched, normal lung
tissue controls (Table 2-1).

Tumor samples were categorized into three groups

respectively: normal, a caspase 9a/9b mRNA ratio of >3.3; moderately dysregulated, a
caspase 9a/9b mRNA ratio of 2.3-3.3; and highly dysregulated, a caspase 9a/9b mRNA
ratio <2.3 (Figure 2-1a,b). A caspase 9a/9b mRNA ratio of ≥4.0 is observed in nontansformed cells. Of the NSCLC samples examined, 36% demonstrated a moderately
dysregulated caspase 9a/9b mRNA ratio (N=149). Even more dramatic, 42% of tumors
demonstrated a > 50% decrease in the caspase 9a/9b mRNA ratio. Thus, the ratio of
caspase 9a/9b mRNA is significantly lower in a high percentage of NSCLC tumors
correlating with loss of activity of the tumor suppressor, caspase 9a.
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Table 2-1. Pathology-verified patient normal tissue and tumor tissue samples analyzed for
their caspase 9a/9b mRNA ratio. Each sample is detailed with diagnosis, group, and ratio
of caspase 9a/9b mRNA.
Pathology-verified patient tumor samples.
Sample

Diagnosis

Group

Caspase
9a/9b ratio

1-I
2-I
3-I
5-I
6-I
7-I
9-I
11-I
13-I
14-I
17-I
19-I
20-I
21-I
24-I
26-I
28-I
30-I
31-I
32-I
38-I
40-I
41-I
43-I
44-I
46-I
47-I
48-I
2-II
6-II
10-II
11-II
14-II
17-II
18-II
21-II
23-II
24-II
27-II
31-II
32-II
35-II
36-II

Normal
Normal
Normal
Normal
Normal
Normal
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Large cell carcinoma
Non-small cell carcinoma
Large cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Large cell carcinoma
Squamous cell carcinoma
Non-small cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Large cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Adenocarcinoma
Squamous cell carcinoma
Non-small cell carcinoma
Large cell carcinoma
Squamous cell carcinoma
Large cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Non-small cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma

Normal
Normal
Normal
Normal
Normal
Normal
High
Moderate
High
Moderate
High
Moderate
High
Normal
Normal
Moderate
Normal
High
Moderate
Moderate
High
Normal
Normal
Moderate
Moderate
High
Moderate
Moderate
High
High
Moderate
Moderate
Moderate
High
High
Moderate
Moderate
Moderate
High
Normal
Normal
High
High

4.0
4.0
3.5
4.0
3.9
4.0
2.0
3.0
2.0
2.3
2.0
2.5
1.0
4.0
3.7
3.2
3.4
1.8
3.0
3.0
1.0
4.0
3.5
2.3
2.6
1.2
2.8
2.3
1.5
2.0
2.6
3.0
2.7
2.0
1.1
2.3
2.3
2.4
2.0
4.5
3.6
1.0
1.1

Sample

Diagnosis

Group

Caspase
9a/9b ratio

37-II
38-II
3-III
7-III
9-III
10-III
12-III
15-III
16-III
19-III
20-III
23-III
25-III
27-III
30-III
31-III
32-III
33-III
34-III
39-III
43-III
44-III
45-III

Squamous cell carcinoma
Large cell carcinoma
Normal
Normal
Squamous cell carcinoma
Large cell carcinoma
Bronchioloalveolar carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Large cell carcinoma
Non-small cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Adenosquamous carcinoma
Large cell carcinoma
Adenosquamous carcinoma
Non-small cell carcinoma
Non-small cell carcinoma
Squamous cell carcinoma

High
High
Normal
Normal
Normal
High
Normal
Normal
Moderate
High
High
Moderate
Moderate
High
Normal
High
Normal
High
High
Normal
Normal
High
High

1.3
1.7
3.9
3.8
3.6
2.0
3.7
4.5
2.3
1.0
2.0
3.2
2.7
1.8
4.0
1.1
3.5
1.7
0.9
3.7
3.9
1.6
1.0

Matched-pair Analysis (Normal tissue vs. Tumor tissue)
1-IV
2-IV
5-IV
6-IV
9-IV
10-IV
11-IV
12-IV
17-IV
18-IV
21-IV
22-IV
23-IV
24-IV
25-IV
26-IV
31-IV
32-IV

Normal 1
Squamous cell carcinoma 1
Normal 2
Large cell carcinoma 2
Normal 3
Large cell carcinoma 3
Normal 4
Large cell carcinoma 4
Normal 5
Squamous cell carcinoma 5
Normal 6
Non-small cell carcinoma 6
Normal 7
Squamous cell carcinoma 7
Normal 8
Squamous cell carcinoma 8
Normal 9
Squamous cell carcinoma 9

Normal
High
Moderate
High
Normal
High
Normal
Normal
Normal
High
Normal
High
Normal
Normal
Normal
Moderate
Normal
Moderate

4.0
0.9
2.8
1.8
4.7
1.7
3.7
3.7
4.5
1.0
4.0
2.1
3.8
3.5
3.5
2.9
3.6
2.4
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Table 2-1 (cont.) Pathologist-verified patient normal tissue and tumor tissue samples
analyzed for their caspase 9a/9b mRNA ratio. Each sample is detailed with diagnosis,
group, and ratio of caspase 9a/9b mRNA.
Pathology-verified patient tumor samples.
Sample
1-I
7-I
10-I
12-I
15-I
16-I
25-I
27-I
33-I
34-I
36-I
37-I
39-I
42-I
45-I
4-II
5-II
7-II
8-II
9-II
12-II
13-II
15-II
16-II
19-II
22-II
25-II
26-II
28-II
29-II
30-II
33-II
34-II
40-II
41-II
43-II
44-II
45-II
46-II
47-II
48-II
K-1
K-3
K-4
K-5
K-6
K-7
K-8
K-9
K-10

Diagnosis

Group

Caspase 9a/9b
ratio

Normal
Normal
Not reported
Not reported
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung

Normal
Normal
High
High
High
High
Moderate
Moderate
High
High
High
High
High
High
High
Moderate
High
Normal
Moderate
High
Moderate
High
High
High
High
High
Moderate
Moderate
Normal
Moderate
Normal
Moderate
High
Moderate
Normal
High
Moderate
Moderate
High
High
High
Moderate
Moderate
Moderate
Moderate
Moderate
Normal
Moderate
Moderate
Normal

4.0
4.0
1.5
1.5
1.5
1.5
3.1
2.8
2.0
1.8
1.0
2.1
1.8
1.6
1.7
2.3
1.2
4.0
3.1
1.8
2.3
1.7
1.1
1.0
2.1
2.1
2.7
3.3
5.1
2.8
4.0
2.4
1.1
2.3
3.5
1.7
3.1
2.3
1.1
1.7
2.2
2.9
3.2
3.4
3.1
3.3
4.4
2.8
2.4
4.0

Sample
K-11
K-19
K-20
K-21
K-24
K-26
4-III
5-III
11-III
13-III
14-III
18-III
21-III
24-III
26-III
28-III
29-III
36-III
38-III
40-III
42-III
46-III
47-III
48-III

Diagnosis

Group

Caspase 9a/9b
ratio

Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Normal
Normal
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung
Adenocarcinoma of lung

Moderate
Normal
Moderate
Moderate
High
High
Normal
Normal
High
Normal
High
Normal
Normal
High
Moderate
High
Moderate
Normal
Moderate
Normal
Normal
High
Moderate
Moderate

3.1
4.5
2.7
3.1
2.2
0.9
4.0
3.6
2.2
3.7
2.1
3.9
4.1
1.6
3.0
1.3
2.4
4.3
3.1
3.9
3.9
1.5
2.3
2.4

Matched-pair Analysis (Normal tissue vs. Tumor tissue)
3-IV
4-IV
7-IV
8-IV
13-IV
14-IV
15-IV
16-IV
27-IV
28-IV
33-IV
34-IV
37-IV
38-IV
39-IV
40-IV
41-IV
42-IV
45-I
46-IV

Normal 1
Adenocarcinoma of lung 1
Normal 2
Adenocarcinoma of lung 2
Normal 3
Adenocarcinoma of lung 3
Normal 4
Adenocarcinoma of lung 4
Normal 5
Adenocarcinoma of lung 5
Normal 6
Adenocarcinoma of lung 6
Normal 7
Adenocarcinoma of lung 7
Normal 8
Adenocarcinoma of lung 8
Normal 9
Adenocarcinoma of lung 9
Normal 10
Adenocarcinoma of lung 10

Normal
High
Normal
High
Normal
High
Normal
Moderate
Normal
High
Normal
Normal
Normal
High
Normal
Moderate
Normal
High
Normal
Normal

4.0
0.9
3.6
1.1
3.9
1.5
3.7
2.6
3.5
1.0
4.0
4.0
4.3
2.2
4.0
2.3
3.8
2.0
3.7
3.9
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Figure 2-1. The caspase 9a/9b mRNA ratio is dysregulated in NSCLC tumors. A
population of cDNAs from pathologist-verified lung adenocarcinomas, squamous cell
carcinomas, and large cell carcinomas (Origene; Rockville, MD) underwent
quantitative/competitive PCR for expression of caspase 9 pre-mRNA splice variants.
a) Representation of the matched pair analysis used to determine the degree of caspase
9a/9b dysregulation in NSCLC tumor samples where N is normal tissue and T is tumor
tissue. A549 samples were analyzed in parallel to provide a caspase 9a/9b mRNA ratio
control. Each cDNA is detailed with diagnosis, tumor grade, caspase 9a/9b ratio group,
and caspase 9a/9b mRNA ratio in Table 2-1. b) Quantitative/competitive PCR analysis
of caspase 9 splice variants demonstrate that 36% of NSCLC tumors present a
moderately dysregulated caspase 9a/9b mRNA ratio (C9a/9b ratio of 2.3-3.3) and 42%
of NSCLC tumors present a highly dysregulated caspase 9a/9b mRNA ratio (C9a/9b
ratio <2.3) (N=147), as determined by densitometric analysis of PCR products.
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Since solid tumors and normal tissue controls are in many cases a combination of
cell types, we then examined a pure population of non-transformed lung epithelial cells,
specifically normal human bronchial epithelial cells (NHBE) and immortalized HBEC-3
cells, for the ratio of caspase 9a/9b mRNA in comparison to the transformed lung epithelial
cell lines, A549, H838, H2347, H358, H2030, H226, H2170, H596, H1792, H1299, H520,
H1703, H292 cells (Table 2-2). HBEC-3 cells present with a normal caspase 9a/9b mRNA
ratio of 4.02±0.15 as do NHBE cells which present with a caspase 9a/9b mRNA ratio of
4.15±0.23 (Figure 2-2a). In contrast, 9 of 11 transformed lung epithelial cells grown under
the exact same culture conditions demonstrated a significant decrease in the caspase 9a/9b
mRNA ratio. Importantly, the disproportionate ratio of caspase 9a/9b mRNA observed in
the transformed lung epithelial cell lines translated to a disproportionate ratio of caspase
9a/9b protein expression (Figure 2-2b). These data indicate that a significant portion of
lung adenocarcinoma tumors and transformed lung epithelial cells demonstrate severe
dysregulation of the alternative splicing of caspase 9 to favor a pro-survival/pro-oncogenic
phenotype.
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Table 2-2. Characterization of NSCLC cell lines
Cell
line

NSCLC
Histology

Mutational Status

Capase 9a/9b ratio

Degree of
Dysregulation

A549

AD

WT p53, k-Ras V12 mutation

1.92

0.16

D

H520

SQ

p53 mutation, WT Ras

2.25

0.15

D

H1703

ADSQ

p53 mutation, WT Ras

3.32

0.08

N

H292

SQ

WT p53, WT Ras

1.72

0.20

D

H2030

AD

WT p53, k-Ras V12 mutation

2.06

0.11

D

H838

AD

p53 mutation, WT Ras

1.42

0.18

D

H596

ADSQ

p53 mutation, WT Ras

2.73

0.09

M

H2170

SQ

p53 mutation, WT Ras

3.65

0.09

N

H2347

AD

WT p53, N-Ras mutation

3.68

0.10

N

H226

SQ

WT p53, WT Ras

2.15

0.12

D

H358

BA

WT p53, k-Ras V12 mutation

3.02

0.16

M

AD, adenocarcinoma; SQ, squamous cell carcinoma; ADSQ, adenosquamous cell carcinoma; BA,
Bronchioalveolar carcinoma; D, dysregulated; M, moderately dysregulated; N, normal.
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Figure 2-2. The caspase 9a/9b mRNA ratio is dysregulated in NSCLC cell lines.
Lung adenocarcinoma and squamous cell carcinoma cell lines were analyzed for the
expression of caspase 9 splice variants. a) Quantitative/competitive RT-PCR analysis of
caspase 9 splice variants and the corresponding caspase 9a/9b mRNA ratio of total
RNA isolated from a variety of NSCLC cell lines and non-transformed HBEC-3KT
cells. Below each cell line and their corresponding caspase 9a/9b mRNA ratio is
depicted graphically. Eight of eleven NSCLC cell lines present with a dysregulated
caspase 9a/9b mRNA ratio. b) In parallel, total protein was isolated and analyzed by
western blotting with anti-caspase 9 antibody to compare the expression of caspase 9a
and caspase 9b splice variants.

44
2.3.2. The PI3-Kinase pathway regulates the alternative splicing of caspase 9.
Since the ratio of caspase 9a/9b mRNA is highly dysregulated in NSCLC, we
hypothesized that one of the major mitogenic signaling pathways activated by oncogenic
mutation regulates the alternative splicing of caspase 9 pre-mRNA to favor the production
of anti-apoptotic caspase 9b. To investigate this hypothesis, these pathways were examined
for effects on the ratio of caspase 9a/9b mRNA utilizing small-molecule inhibitors at doses
and times well characterized in the scientific literature and previously utilized in studies on
A549 cells206-212. Treatment of A549 cells with the following inhibitors, the MAP Kinase
inhibitor PD98059 [50μM] and SB202190 [10µM], MEK 1/2 inhibitor U0126 [10μM],
Rho-kinase inhibitor Y-27632 [10μM], Casein Kinase II inhibitor DMAT [10μM], Src
kinase inhibitor I [25μM], and JNK Inhibitor II, SP600125, [10µM] had no effect on the
alternative splicing of caspase 9 (Table 2-3).

In contrast, treatment of A549 lung

adenocarcinoma cells with the PI3-K inhibitor, LY294002 [50μM], resulted in a significant
increase in the ratio of caspase 9a/9b splice variants compared to the inactive, structurallyrelated compound, LY303511 (Figure 2-3a,b). Specifically, the caspase 9a/9b mRNA ratio
increased from 2.10  0.18 for control samples to 3.91  0.08 for inhibitor treated samples
(p < 0.0008 (n=6), corresponding to approximately a 2-fold increase in the caspase 9a/9b
ratio. Since PI3-Kinase inhibition increases caspase 9a with a parallel decrease in caspase
9b, these data demonstrate that PI3-Kinase regulates the alternative splicing of caspase 9 in
an anti-apoptotic/pro-survival manner. Furthermore, the inhibition of PI3Kinase effectively
returned the caspase 9a/9b mRNA ratio to the ratio observed in non-transformed lung
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epithelial cells. Importantly, this effect on the caspase 9a/9b ratio translated to the protein
level (Figure 2-3b).

Table 2-3. Mitogen signaling pathways demonstrating no involvement in the alternative
splicing of caspase 9 as analyzed by small molecule inhibitors.
Mitogenic Pathways Investigated

Inhibitor

Concentration

Mitogen Activated Protein Kinase (MAPK)

U0126

10µM

PD98059

50µM

SB202190

10µM

Rho Kinase (ROCK)

Y-27632

10µM

Casein Kinase (CK)

DMAT

10µM

Src Family Tyrosine Kinases

Src Kinase Inhibitor I

25µM

Protein Kinase C

Go6983

10µM

Go6976

10µM

mTOR

Rapamycin

10µM

Glycogen Synthase Kinase (GSK)

SB216763

10µM

c-Jun-N-Terminal Kinase (JNK/SAP Kinase)

SP600125

10µM

To determine the translatability of the mechanism, H838, H2030, H358, H292, and
H520 cells (all presenting a dysregulated caspase 9a/9b mRNA ratio) were also treated
with LY294002 (Figure 2-3c). As with the A549 cells, the caspase 9a/9b mRNA ratio was
dramatically increased (H838 cells from 1.24 ± 0.05 to 3.29 ± 0.19; H2030 cells from 2.30
± 0.08 to 3.74 ± 0.08; H358 cells from 3.11 ± 0.09 to 4.13 ± 0.12; H292 cells from 2.01 ±
0.09 to 4.11 ± 0.11; and H520 cells from 2.35 ± 0.08 to 3.91 ± 0.13). Therefore, the ability
of the PI3-Kinase pathway to regulate the alternative splicing of caspase 9 translates to
multiple NSCLC cell lines.
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LY303511 [50μM]
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caspase 9a
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Figure 2-3. Effect of PI3-Kinase inhibition on the alternative splicing of caspase 9
pre-mRNA. a) Quantitative/competitive RT-PCR analysis of caspase 9 splice variants
and the corresponding caspase 9a/9b mRNA ratios from A549s treated with either
LY294002 [50uM] or structurally inactive control LY303511 [50uM]. The ratio of
caspase 9a to caspase 9b mRNA was determined by densotimetric analysis of RT-PCR
fragments. b) Twenty four hours post-treatment, total protein was isolated and analyzed
by western blotting with anti-caspase 9 antibody to compare the expression of caspase
9a and caspase 9b splice variants. c) To determine the translatability of the mechanism,
H838s, H2030s, H358s, H292s, and H520s were treated with either LY294002 [50uM]
or structurally inactive control LY303511 [50uM]. Twenty four hours post-treatment,
total RNA was isolated and quantitative/competitive RT-PCR performed. The ratio of
caspase 9a to caspase 9b mRNA was determined by densitometric analysis of RT-PCR
fragments. Data are expressed as means s.d. P-values in pairwise comparisons to the
control, p values < 0.01 were considered significant. Data are representative of three
separate determinations on two separate occasions.
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2.3.3 Akt, downstream of PI3-Kinase, regulates the alternative splicing of caspase 9.
Akt/PKB, SGK, PKCξ, and PKCδ are downstream of PI3-Kinase, all of which have
been well described in the literature213. To investigate the downstream effector of PI3Kinase responsible for regulating the alternative splicing of caspase 9, well-characterized
small-molecule inhibitors in conjunction with RNAi technology was employed. Treatment
of A549 cells with the Protein Kinase C inhibitors GÖ6976 [10μM] and GÖ6983 [10μM]
(Table 2-3; Figure 2-4a,b), resulted in no significant change in the caspase 9a/b mRNA
ratio in A549 cells. Conversely, treatment of A549 cells with the Akt inhibitor, AKT VIII
[25μM] and the phosphatidylinositol analog, SH-5 [10µM], which inhibits the activation of
Akt, resulted in an increased caspase 9a/9b mRNA ratio to the same extent as PI3-Kinase
inhibition (from 2.10  0.11 for DMSO control samples to 4.03  0.13 for Akt inhibitor
VIII-treated samples (n=6) p<0.01; and from 2.10 ± 0.08 for DMSO control samples to
3.73 ± 0.13 for SH-5-treated samples (n=4) p<0.01) (Figure 2-5a,b). In addition, treatment
of A549 cells with the PDK1 inhibitor OSU03012 [10μM] or downregulation of PDK1
using siRNA (Figure 2-5c,d) resulted in a significantly increased caspase 9a/9b mRNA
ratio (from 2.25 ± 0.13 for control samples to 4.05 ± 0.22 for inhibitor treated samples
(n=4), p<0.01; and from 2.13 ± 0.09 for siRNA control samples to 3.78 ± 0.21 for siPDK1
treated samples (n=4) p<0.01).
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a
DMSO

[10µM]
Go6983
caspase 9a
caspase 9b

2.02

0.13 2.33

0.07

caspase 9a/caspase 9b

b
DMSO

[10µM]
Go6776
caspase 9a
caspase 9b

2.11

0.05 1.92

0.08

caspase 9a/caspase 9b

Figure 2-4. Inhibition of Protein Kinase C (PKC) does not affect the alternative
splicing of caspase 9 pre-mRNA. Quantitative/competitive RT-PCR analysis of
caspase 9 splice variants and the corresponding caspase 9a/9b mRNA ratios from
A549s treated with either DMSO control (0.1%), a) Gö6983 [10μM] or b) Gö6776
[10μM]. The ratio of caspase 9a to caspase 9b mRNA was determined by densitometric
analysis of RT-PCR fragments. Data are expressed as mewereans s.d. P-values in
pairwise comparisons to the control; p values < 0.01 considered significant. Data are
representative of three separate determinations on two separate occasions.
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Figure 2-5. Inhibition of Akt activation regulates the alternative splicing of caspase
9 pre-mRNA. Quantitative/competitive RT-PCR analysis of caspase 9 splice variants
and the corresponding caspase 9a/9b mRNA ratios from A459 cells treated DMSO
control or a) Akt inhibitor VIII [25µM], b) SH-5 [25µM], or c) OSU03012 [10µM].
The ratio of caspase 9a to caspase 9b mRNA was determined by densitometric analysis
of RT-PCR fragments. d) Quantitative/competitive RT-PCR analysis of caspase 9 splice
variants and the corresponding caspase 9a/9b mRNA ratios from A459s transfected
with scrambled siRNA [100nM] or PDK1 siRNA [100nM]. The ratio of caspase 9a to
caspase 9b mRNA was determined by densitometric analysis of RT-PCR fragments. To
confirm protein knockdown, total protein lysate was subjected to western
immunoblotting against anti-PDK1 antibody. Data are expressed as means s.d. Pvalues in pairwise comparisons to the control; p values < 0.01 were considered
significant. Data are representative of three separate determinations on two separate
occasions.
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Since Akt inhibition increases caspase 9a with a parallel decrease in caspase 9b,
these data demonstrate that an Akt isoform regulates the alternative splicing of caspase 9 in
an anti-apoptotic/pro-survival manner. This effect was specific for the alternative splicing
of caspase 9 as treatment of A549 cells with AKT VIII inhibitor demonstrated no effect on
the alternative splicing of caspase 8, caspase 2, and Bcl-x pre-mRNA (Figure 2-6).
Furthermore, co-treatment of A549 cells with both AKTVIII and LY294002 could not
further increase the caspase 9a/9b mRNA ratio demonstrating a linear pathway and Akt as
the downstream effector for PI3 kinase (Figure 2-7).
To examine the Akt isoform responsible for regulating the alternative splicing in
A549 cells, small interference RNA (siRNA) technology was again utilized. Western
immunoblotting demonstrated that A549 cells were essentially devoid of Akt3, but
expressed both Akt1 and Akt2, thus siRNA was utilized for only Akt1 and Akt2.
Downregulation of Akt1 using multiplex siRNA resulted in no change in the caspase 9a/9b
mRNA ratio with respect to control siRNA treated cells (p0.34) (Figure 2-8a).

In

contrast, downregulation of Akt2 using multiplex siRNA resulted in a dramatic increase in
the caspase 9a/b ratio from 2.10  0.05 to 4.09  0.22, p<0.01 (n=5) (Figure 2-8b). As with
the previous studies on PI3-Kinase, this effect on the caspase 9a/9b mRNA ratio translated
to the protein level (Figure 2-8c).
To further validate a role for Akt in regulating the alternative splicing of caspase 9,
ectopic expression of a constitutively-active Akt2 (always membrane bound via
myristoylation) induced a significant decrease in the caspase 9a/9b mRNA ratio (Figure 29a). Furthermore, ectopic expression of PTEN, a negative regulator of the Akt signaling
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pathway, induced the contrasting effect (Figure 2-9b). Therefore, Akt2 regulates the
alternative splicing of caspase 9 via PIP3 membrane interactions in A549 cells, and also
requires PDK-1 phosphorylation.
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[25µM]
AKT VIII

Bcl-x(L)
Bcl-x(s)
5.32

0.38

b
DMSO

5.56

0.11

Bcl-x(L)/Bcl-x(s)

[25µM]
AKT VIII
caspase 8 L

caspase 8
0.48

0.02

c
DMSO

0.52

0.01

caspase 8L/caspase 8

[25µM]
AKT VIII
caspase 2S
caspase 2L

9.13

0.32

8.91

0.34

caspase 2S/caspase 2L

Figure 2-6. Inhibiton of Akt does not affect the alternative splicing of Bcl-x, capase
8, or caspase 2. A459 cells were treated with Akt inhibitor VIII [25µM]. Twenty-four
hours post-treatment, RNA was isolated and quantitative/competitive RT-PCR
performed for a) Bcl-x splice variants, b) caspase 8 splice variants, and c) caspase 2
splice variants. The ratio of PCR products was determined by densitometric analysis of
RT-PCR fragments. Data are expressed as means s.d.
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caspase 9a

caspase 9a
caspase 9a/ caspase 9b

Figure 2-7. The alternative splicing of caspase 9 is regulated by PI3-Kinase/Akt in
a linear manner. Quantitative/competitive RT-PCR analysis of caspase 9 splice
variants and the corresponding caspase 9a/9b mRNA ratios from A459s treated with
DMSO control (0.1%), LY294002 [50μM], Akt VIII [25μM], or both LY294002
[50μM] and Akt VIII [25μM] in combination. The ratio of caspase 9a to caspase 9b
mRNA was determined by densitometric analysis of RT-PCR fragments. Data are
expressed as means s.d. P-values in pairwise comparisons to the control; p values <
0.01 were considered significant. Data are representative of three separate
determinations on two separate occasions.
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Figure 2-8. Downregulation of Akt2 increases the caspase 9a/9b mRNA ratio in
A549 cells. Quantitative/competitive RT-PCR analysis of caspase 9 splice variants and
the corresponding caspase 9a/9b mRNA ratios from A549s transfected with control
siRNA, a) AKT1 siRNA, or b) AKT2 siRNA. Knockdown of AKT1 and AKT2 were
confirmed by western blot. The ratio of caspase 9a to caspase 9b mRNA was
determined by densitometric analysis of RT-PCR fragments. Data are expressed as
means s.d. P-values in pairwise comparisons to the control; p values < 0.01 were
considered significant. c) Total proteins from A549s transfected with the indicated
siRNAs were also subjected to western blot analysis to demonstrate the change in the
ratio of caspase 9a to caspase 9b protein expression.
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caspase 9a
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3.63
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Figure 2-9. Akt2 regulates the alternative splicing of caspase 9 via PIP3 membrane
interactions in A549 cells. A459 cells were infected with either a) caAkt2 adenovirus
(25MOI) or b) PTEN adenovirus (25MOI). Fourty-eight hours post-infection, RNA
was isolated and quantitative/competitive RT-PCR performed. The ratio of caspase 9a
to caspase 9b PCR products was determined by densitometric analysis of RT-PCR
fragments. Data are expressed as means s.d. P-values in pairwise comparisons to the
control; p values < 0.01 were considered significant.

To determine the translatability of this mechanism to other NSCLC cell lines,
H2030, H292, H358, and H520 cells were also treated with the AKT VIII inhibitor
[50µM]. As with the A549s, all four cell lines also demonstrated a dramatic increase in the
caspase 9a/9b mRNA ratio in the presence of this inhibitor (Figure 2-10). Additionally,
Akt1 and Akt2 was downregulated via siRNA in H358 cells to determine the Akt isoform
responsible for regulating the alternative splicing of caspase 9. In contrast to A549s,
downregulation of Akt1 but not Akt2 induced a significant increase in the caspase 9a/9b
mRNA ratio (Figure 2-11 and data not shown). Therefore, multiple Akt isoforms have the
potential to regulate the alternative splicing of caspase 9 in NSCLC cells.
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Figure 2-10. Inhibition of Akt regulates the alternative splicing of caspase 9 in
multiple NSCLC cell lines. Quantitative/competitive RT-PCR of caspase 9 splice
variants and the corresponding caspase 9a/9b mRNA ratios of H2030s, H358s, H292s,
and H520s treated with Akt inhibitor VIII [25µM]. The ratio of caspase 9a to caspase
9b mRNA was determined by densitometric analysis of RT-PCR fragments. Data are
expressed as means s.d. P-values in pairwise comparisons to the control; p values <
0.01 were considered significant.
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Figure 2-11. Knockdown of Akt1 regulates the alternative splicing of caspase 9 in
H358 cells. Quantitative/competitive RT-PCR analysis of caspase 9 splice variants and
the corresponding caspase 9a/9b mRNA ratios from H358s transfected with control
siRNA and AKT1 siRNA. Knockdown of AKT1 and AKT2 were confirmed by
western blot analysis. The ratio of caspase 9a to caspase 9b mRNA was determined by
densitometric analysis of RT-PCR fragments. Data are expressed as means s.d. Pvalues in pairwise comparisons to the control; p values < 0.01 were considered
significant.
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2.4. Discussion
Lung cancer is the leading cause of cancer mortality in the Western world and the
5-year survival rate for all stages is only ~15%

214,215

. From a histological point of view,

lung cancer can be classified as non-small cell (NSCLC) or small cell lung cancer (SCLC);
80% of lung cancers diagnosed are NSCLCs, and 20% are SCLCs216. NSCLCs can be
further subdivided to include adenocarcinomas of the lung, squamous cell carcinomas of
the lung, and large cell carcinomas of the lung.
The data presented in this chapter demonstrates that the alternative splicing of
caspase 9 is dysregulated in a pro-survival manner (lower caspase 9a/9b mRNA ratio) in a
large population of pathologist-verified human NSCLC tumor samples and transformed
lung cancer cells. Specifically, 79% of tumors samples examined presented with a
moderate to severely dysregulated caspase 9a/9b mRNA ratio.

Similarly, 8 of 11

transform lung cancer cell lines presented with a moderate to severely dysregulated
caspase 9a/9b mRNA ratio. These findings prompted us to investigate the signaling
pathways responsible for regulating the alternative splicing of caspase 9 in this prosurvival fashion. Utilizing small-molecule inhibitors and siRNA technologies, the PI3Kinase/Akt pathway was identified as the major mitogenic signaling pathway responsible
for regulating the inclusion/exclusion of the exon 3,4,5,6 cassette of caspase 9.

This

finding translated to multiple NSCLC cell lines, including adenocarcinomas and squamous
cell carcinomas.

CHAPTER 3
THE ROLE OF EGFR IN THE ALTERNATIVE SPLICING OF CASPASE 9

3.1. Introduction
Lung cancer is characterized by the accumulation of multiple genetic alterations
resulting in the activation of oncogenes or inactivation of tumor suppressor genes39. In
essentially all epithelial cancers, including NSCLC, one or more members of the family of
epidermal growth factor receptor (EGFR) genes are either overexpressed or dysregulated40.
Aberrant signaling of EGFR family members can occur by the following three fundamental
mechanisms: activating gene mutations, increased gene copy number (via amplification or
polysomy), and altered ligand expression (potentially leading to autocrine stimulatory
loops)217. Mutations in exons encoding the tyrosine kinase domains of EGFR are found in
10% of lung adenocarcinomas218. Of those EGFR mutations, nearly 90% are either short
deletions in exon 19 (i.e. ΔE746-A750 del) or point mutations that result in substitution of
arginine for leucine at amino acid 858 (L858R)218. Recently, Hirch et. al. reported that 62%
of NSCLCs of adenocarcinoma and squamous cell subtypes exhibited EGFR protein
overexpression41, which is often associated with poor prognosis42. In addition to EGFR
expression, epidermal growth factor (EGF) and transforming growth factor-α (TGF-α), two
of its cognate ligands, are also freely expressed in NSCLCs, leading to over-stimulation of
downstream mitogenic signaling pathways43,44.
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The PI3-Kinase/Akt pathway is one of the major signaling networks downstream of
EGFR signaling. Since the PI3-Kinase/Akt pathway was demonstrated to regulate the
alternative splicing of caspase 9 pre-mRNA in a pro-survival manner, we investigated the
role of EGFR signaling on the alternative splicing of caspase 9 pre-mRNA. Aberrant
EGFR signaling in cancer cells can accelerate tumor progression and much effort has
focused on the development of drugs that specifically inhibit EGFR tyrosine kinase
activity217,219,220. Erlotinib (Tarceva, OSI-774) is one of the most extensively evaluated
tyrosine kinase inhibitors of the EGFR currently in clinical trials221. This year, Jackman,
D.M. et al. reported on the impact of EGFR mutations on the clinical outcomes in
previously untreated NSCLC patients222. Interestingly, patients harboring an exon 19
deletion in EGFR had a longer median prolonged time to progression (14.6 versus 9.7
months) and longer overall survival (30.8 versus 14.8 months) compared to patients
harboring the 858R mutation222. Therefore, we investigated the effect of modulating the
caspase 9a/9b mRNA ratio on the sensitivity of A549 cells to erlotinib, and on the ability
of the E746-A750 del EGFR-expressing HBEC3-KT cells to confer anchorageindependent growth.

3.2. Materials and Methods
3.2.1. Cell Culture
A549 cells were grown in 50% RPMI 1640 (Invitrogen Life Technologies,
Carlsbad, CA) and 50% Dulbecco's modified Eagle's medium (Invitrogen Life
Technologies, Carlsbad, CA) supplemented with L-glutamine, 10% (v/v) fetal bovine
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serum (Sigma), 100 units/ml penicillin G sodium (Invitrogen Life Technologies, Carlsbad,
CA), and 100 μg/ml streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA).
A549s were purchased from ATCC (Rockville, MD, USA). HBEC-3KT cell lines were a
provided by John D. Minna and previously described223. Briefly, the HBEC-3 (HBEC3KT) immortalized normal cell line was established by introducing mouse Cdk4 and
hTERT into normal HBECs obtained from a 65 year old woman without cancer223.
KRASV12, wild-type EGFR and mutant EGFRs were introduced into the HBEC3-KT cell
line as previously described223.

HBEC-3KT cell lines were cultured with keratinocyte

serum-free medium (K-SFM) (Invitrogen Life Technologies, Carlsbad, CA) containing
50μg/ml bovine pituitary extract with or without 5ng/ml recombinant epidermal growth
factor (Invitrogen Life Technologies, Carlsbad, CA). All cells were maintained at less than
80% confluency under standard incubator conditions (humidified atmosphere, 95% air, 5%
CO2, 37 °C).

3.2.2. Quantitative/Competitive RT-PCR
Total RNA from cell lines were isolated using the RNeasy® Mini Kit (Qiagen Inc.,
Valencia, CA) according to the manufacturer‘s protocol. Total RNA (1 μg) was reversetranscribed using Superscript III reverse transcriptase (SuperScript™ First-Strand
Synthesis System for RT-PCR, Invitrogen™, Carlsbad, CA) and oligo (dT) as the priming
agent. After 50 min of incubation at 42°C, the reactions were terminated by heating at
70°C for 15 min. Template RNA was then removed using RNase H (Invitrogen, Carlsbad,
CA). To quantitatively evaluate the expression of endogenous caspase 9 splice variants, an
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upstream 5‘ primer to caspase-9 (5‘-GCT CTT CCT TTG TTC ATC TCC-3‘) and a 3‘
primer (5‘-CAT CTG GCT CGG GGT TAC TGC-3‘) (Integrated DNA Technologies, Inc.,
Coralville, IA) were used. Using these primers, 20% of the reverse transcriptase reaction
was amplified for 25 cycles (94°C, 30 s melt; 57°C, 30 s anneal; 72°C, 1 min extension)
using Platinum Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA). Gene
products produced from endogenous caspase 9 PCR resulted in a 1248 base pair caspase 9a
splice variant and 798 base pair caspase 9b splice variant. The final PCR products were
resolved on a 5% TBE acrylamide gel electrophoresis, stained

with SYBR® Gold

(Invitrogen™, Carlsbad, CA) and visualized using a Molecular Imager® FX (Bio-Rad)
with a 488 nm EX (530 nm BYPASS) laser.

3.2.3. Western Immunoblotting
Cells were lysed using CelLytic™ lysis Buffer (Sigma-Aldrich) supplemented with
protease Inhibitor cocktail (Sigma-Aldrich). Protein samples (5 μg) were subjected to 10%
SDS-PAGE, transferred to a polyvinylidene difluoride membrane (PDVF) (Bio-Rad) and
blocked in 5% milk/1 X PBS – 0.1% Tween (M-PBS-T) for 2 h. Primary antibodies were
anti-caspase 9 (1:1,000, Assay Designs), anti-Akt1 (1:1,000, Santa Cruz), anti-Akt2
(1:1,000, Santa Cruz), and anti-β-actin (1:5,000, Sigma-Aldrich). Secondary antibodies
were HRP-conjugated goat anti-mouse or anti-rabbit (1:5,000, Sigma-Aldrich).
Immunoblots were developed using Pierce enhanced chemiluminescence (ECL) reagents
and Bio-Max film.
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3.2.4. Small interfering RNA transfection
For inhibition of Akt1 and Akt2 expression, cell lines were transfected with either
Akt1 SMARTpool multiplex, Akt2 SMARTpool multiplex, or scrambled control siRNA
(Dharmacon; Lafayette, CO) using Dharmafect 1 transfection reagent (Dharmacon;
Lafayette, CO) following the manufacturer‘s protocol. Briefly, cell lines were plated in sixwell tissue culture dishes and allowed to rest overnight. At 50% confluence, cells were
transfected with siRNA [100nM] using Dharmafect 1 in Opti-Mem I reduced-serum
medium. Forty-eight hours post-transfection, RNA and/or protein were isolated.

3.2.5. Inhibitor studies
For Inhibitor studies, 1.2 x 105 cells were plated into 6-well tissue culture plates.
The following day media was removed and replaced with the appropriate complete growth
media. Cells were subsequently treated with sham control (1:1000) or the appropriate
concentration of active inhibitor (1:1000) (Calbiochem). Twenty-four hours posttreatment, total RNA and/or protein was isolated.

3.2.6. Clonogenic and soft agar assays
For clonogenic assays, 150 viable cells were seeded into 6-well tissue culture
dishes with complete growth media. Two hours post-plating, cells were treated with the
appropriate concentration of erlotinib (1:1,000 dilution). The following day, cells were
rinsed with 1xPBS and allowed to grow in complete growth media for 12 days. Colonies
were visualized and counted following fixation with methanol and staining with 0.1%
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crystal violet. For soft agar assays using HBEC-3KT cell lines, 1,000 viable cells were
suspended and plated in 0.37% agar (Fisher Scientific) in K-SFM medium supplemented
with 20% of fetal bovine serum and 50 µg/mL bovine pituitary extract into 6-well tissue
culture plates, and were layered over a 0.6% agar base in the same medium used to
suspend the cells.

The number of microscopically visible colonies (>40 cells) were

counted 4 weeks later. For soft agar assays using NSCLC cell lines following cell sorting
(described below), 5,000 viable cells were suspended and plated in 0.3% agar (Fisher
Scientific) in their appropriate growth media with all supplements (described above) into
6-well tissue culture plates, and were layered over a 0,6% agar base in the same media
used to suspend cells. The number of microscopically visible colonies (>40 cells) were
counted 2 weeks later.

3.2.7. Stable transfections
To generate a HBEC3-KT, E746-A750 del EGFR clonal cell line stably expressing
shRNA knockdown of caspase 9b, 1.5 x 104 cells were plated and infected with either
shRNA caspase 9b lentiviral particles (20MOI) or control shRNA lentiviral particles
(20MOI) (Lentigen). The following day, lentivirus medium was removed and replaced
with complete KSFM medium (described above). Forty-eight hours after infection, drug
selection was started with 20ug/mL hygromycin (Sigma-Aldrich) and continued for 11
days. To generate a ―batch culture‖ A549 cell line stably expressing shRNA knockdown of
caspase 9b, 1.5 x 104 cells were plated and infected with either shRNA caspase 9b
lentiviral particles (20MOI) or control shRNA lentiviral particles (20MOI) (Lentigen).

64
The following day, lentivirus medium was removed and replaced with complete A549
medium (described above). Forty-eight hours after infection, drug selection was started
with 50ug/mL hygromycin (Sigma-Aldrich) and continued for 11 days. To generate a
―batch culture‖ A549 cell line stably expressing ectopic caspase 9b cDNA, 1.5 x 10 4 cells
were plated in 35mm tissue culture dishes. The following day, 0.5ug of pcDNA3.1 (-)
zeocin containing caspase 9b was transfected into the cells using Effectene (Qiagen Inc.,
Valencia, CA) following the manufacture‘s protocol. Twenty-four hours after transfection,
cells were rinsed with 1xPBS and selection started with 50µg/mL zeocin (Invitrogen Life
Technologies, Carlsbad, CA) and continued for 11 days.

3.3. Results
3.3.1. EGFR overexpression or mutation affects the alternative splicing of caspase 9
via activation of the PI3-Kinase/Akt pathway.
The PI3-Kinase pathway is constitutively activated by a number of oncogenic
mutations including those common in NSCLC, such as k-ras (e.g. k-RasV12) and EGFR
overexpression/mutation. Therefore, we examined whether these two common oncogenes
in NSCLC affected the alternative splicing of caspase 9 in non-transformed human
bronchial epithelial cells (HBEC-3KT cells). Whereas low expression of k-RasV12 in
HBEC-3KT cells223 had no discernable effect on the ratio of caspase 9a/9b mRNA, the
overexpression of wild-type EGFR, the expression of L858R mutation in EGFR, and the
expression of the del E746-A750 EGFR mutation induced a significant reduction in the
caspase 9a/9b mRNA ratio (Figure 3-1). Importantly, the del E746-A750 mutation of
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EGFR induced the most significant decrease in the caspase 9a/9b mRNA ratio correlating
with the ability of this mutant to induce anchorage independent growth223. As with the lung
adenocarcinoma and squamous cell lines, the ability of EGFR mutation to induce a
lowering of the caspase 9a/9b ratio was dependent on the PI3-Kinase/Akt pathway.
Treatment of E746-A750 del expressing HBEC-3KT cells with LY294002 and Akt
inhibitor VIII also increased the ratio of caspase 9a/9b mRNA to levels comparable with
normal

HBEC-3KT

cells

(Figure

3-2a,b).

These

data

suggest

that

EGFR

overexpression/mutation correlates with Akt activation affecting the alternative splicing of
the tumor suppressor, caspase 9.

caspase 9a
caspase 9b

4.02

0.12

3.11

0.09

3.02

0.18

2.61

0.10

caspase 9a/caspase 9b

Figure 3-1. EGFR overexpression or mutation affects the alternative splicing of
caspase 9 pre-mRNA. Total RNA was isolated from vector control-, wild-type EGFR-,
L858R EGFR-, and E746-A750 del EGFR-expressing HBEC-KT cells.
Quantitative/competitive RT-PCR analysis was performed of caspase 9 splice variants
and the corresponding caspase 9a/9b mRNA ratios depicted. The ratio of caspase 9a to
caspase 9b mRNA was determined by densitometric analysis of RT-PCR fragments.
Data are expressed as means s.d. P-values in pairwise comparisons to the control; p
values < 0.01 were considered significant.
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caspase 9a

caspase 9b
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b
DMSO
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caspase 9a/9b

[25µM]
AKT VIII
caspase 9a
caspase 9b

2.60  0.11

3.91  0.14 caspase 9a/caspase 9b

Figure 3-2. The PI3-Kinase/Akt pathway regulates the alternative splicing of
caspase 9 in E746-A750 del EGFR-expressing HBEC-3KT cells. Quantitative
competitive RT-PCR analysis of caspase 9 splice variants and the corresponding
caspase 9a/9b mRNA ratios from E746-A750 del EGFR-expressing HBEC-3KT cells
treated with a) LY303511 control compound [50µM] or LY294002 [50µM], and b)
DMSO control (0.1%) or Akt inhibitor VIII [25µM]. The ratio of caspase 9a to caspase
9b mRNA was determined by densitometric analysis of RT-PCR fragments. Data are
expressed as means s.d. P-values in pairwise comparisons to the control; p values <
0.01 were considered significant.

We extended these results by examining the AKT isoform responsible for
regulating the alternative splicing of caspase 9 pre-mRNA in HBEC-3KT cells harboring
the del E746-A750 mutation in EGFR. Interestingly, siRNA against both AKT1 and
AKT2 (Figure 3-3), but not AKT3 (data not shown), resulted in a significantly increase
caspase 9a/caspase 9b mRNA ratio as compared to control siRNA (from 2.81 ± 0.05 for
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siRNA control samples to 4.01 ± 0.13 for siAKT1 samples (n=3), p<0.01; and to 3.72 ±
0.11 for siAKT2 treated samples (n=3) p<0.01). Therefore, multiple AKT isoforms are
responsible for regulating the alternative splicing of caspase 9 in NSCLC.

siCon

siAkt1

siAkt2
caspase 9a

caspase 9b
2.65 ± 0.09

4.01 ± 0.13

3.72 ± 0.11

caspase 9a/9b

Akt1

Akt2

β-actin

β-actin

Figure 3-3. Knockdown of Akt1 or Akt2 in E746-A750 del EGFR-expressing
HBEC-3KT cells results in an increased caspase 9a/9b mRNA ratio.
Quantitative/competitive RT-PCR analysis of caspase 9 splice variants and the
corresponding caspase 9a/9b mRNA ratios from E746-A750 del EGFR-expressing
HBEC-KT cells treated with either scrambled control siRNA, Akt1 siRNA, or Akt2
siRNA. Knockdown of Akt1 and Akt2 were confirmed by western blot analysis. The
ratio of caspase 9a to caspase 9b mRNA was determined by densitometric analysis of
RT-PCR fragments. Data are expressed as means
s.d. P-values in pairwise
comparisons to the control; p values < 0.01 were considered significant.
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3.3.2. Modulation of the alternative splicing of caspase 9 regulates the ability of
erlotinib to inhibit colony formation of A549s.
Previous results presented demonstrate the alternative splicing of caspase 9 splicing
is regulated via the EGFR/PI3-Kinase/Akt pathway. This prompted us to investigate the
effect of erlotinib, a tyrosine kinase inhibitor of the human EGFR, on the caspase 9a/9b
mRNA ratio. Treatment of A549s with erlotinib led to a dose-dependent increase in the
caspase 9a/9b mRNA ratio (Figure 3-4). Next, the effect of lowering the caspase 9a/9b
mRNA ratio on the sensitivity of A549 cells to erlotinib was examined in attempt to
validate our hypothesis that a reduced ratio of caspase 9a/9b mRNA observed in non-small
cell lung carcinomas was relevant in a clinical setting. Ectopic expression of caspase 9b
cDNA completely inhibited the ability of erlotinib to suppress cell survival, as determined
by clonogenic survival assays (Figure 3-5a). In contrast, downregulation of caspase 9b
sensitized A549 cells to erlotinib, dramatically reducing the IC50 from 16.5µM for control
shRNA cells to 4.5µM for C9bshRNA cells (Figure 3-5b).
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caspase 9a
caspase 9b

0.1%
DMSO

Erlotinib 500nM – 20µM

Figure 3-4. Treatment of A549s with erlotinib results in a dose-dependent increase
in the caspase 9a/9b mRNA ratio. Quantitative competitive RT-PCR analysis of
caspase 9 splice variants from E746-A750 del EGFR-expressing HBEC-3KT cells
treated with increasing doses of erlotinib (dose-dependent response).
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Figure 3-5. Modulation of the alternative splicing of caspase 9 regulates the ability
of erlotinib to inhibit liquid colony formation of A549 cells. A549 cells expressing
a) ectopic caspase 9b cDNA or vector control, and b) caspase 9b shRNA or control
shRNA, were plated in triplicate 35mm plates in the presence of
varying
concentrations of erlotinib. The following day, erlotinib-containing medium was
removed and replaced with new medium. Cells were cultured for 12 days following
staining with crystal violet and colony counting.
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3.3.3. The alternative splicing of caspase 9 plays a major role in maintaining the
anchorage-independent growth of A549 cells.
Due to the fact that a large majority of NSCLC tumors and cell lines present with a
dysregulated caspase 9a/9b ratio, and the knowledge that caspase 9a is a tumor suppressor,
we hypothesized that the alternative splicing of caspase 9 is involved in maintaining the
transformed phenotype of NSCLC. To determine the biological role of the alternative
splicing of caspase 9, A549 ―batch culture‖ cell lines stably expressing either caspase 9b
cDNA or caspase 9b shRNA were produced and assayed for their ability to grow in soft
agar. Ectopic expression of caspase 9b (a two-fold increase in caspase 9b expression and
50% reduction in the ratio of caspase 9a/9b mRNA) significantly increased the ability of
A549 cells to grow in soft agar (Figure 3-6a). In contrast, stable expression of caspase 9b
shRNA significantly reduced the ability of A549 cells to grow in soft agar (Figure 3-6b).
Thus, these data suggest that the alternative splicing of caspase 9 plays a role in regulating
the anchorage-independent growth of A549 cells.

3.3.4. EGFR (E746-A750 del) mutation requires the lowering of the caspase 9a/9b
mRNA ratio to confer anchorage-independent growth to HBEC-3KT cells.
The E746-A750 del EGFR mutation in HBEC-3KT cells conferred anchorageindependent growth223 and demonstrated the greatest effect on lowering the caspase 9a/9b
mRNA ratio. In addition, results presented above have provided biological evidence for
the role of caspase 9b in regulating the anchorage-independent growth of A549s.Therefore,
we hypothesized that increased expression of caspase 9b was a major mechanism in
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conferring anchorage-independent growth of HBEC-3KT cells. To test this hypothesis, an
E746-A750 del EGFR clonal cell line (HBEC-3KT Δ746/C9b-dr) stably expressing
caspase 9b shRNA was produced. The expression of caspase 9b in the HBEC-3KT
Δ746/C9b-dr clonal cell line was reduced to normal immunoreactive levels and this cell
line presented with a caspase 9a/caspase 9b mRNA ratio comparable to the ratio observed
in HBEC-3KT cells (Figure 3-7a,b).

Validating our hypothesis, the HBEC-3KT

Δ746/C9b-dr cells demonstrated a complete loss of anchorage-independent growth
compared to E746-A750 del EGFR cells stably expressing control shRNA (Figure 3-7c).
These effects did not require stable expression and were not due to integration artifacts as
short term/transient downregulation of caspase 9b using shRNA lentiviral particles also
inhibited the anchorage-independent growth of E746-A750 del EGFR cells (Figure 3-8a).
Downregulation of caspase 9b was again confirmed in these cells via RT-PCR of caspase 9
splice variants and western blot analysis (Figure 3-8b,c). Thus, the distal mechanism of
caspase 9 splicing plays a major role in the ability of EGFR signaling to confer anchorageindependent growth.
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Figure 3-6. The alternative splicing of caspase 9 regulates the anchorageindependent growth of A549 cells. A549 cells stably expressing a) ectopic caspase 9b
cDNA or vector control, and b) caspase 9b shRNA or control shRNA, were assayed for
their ability to grow in soft agar. A total of 1,000 cells were plated per dish and
cultured for 2 weeks before counting. Depicted is the quantification of the number of
colonies counted, represented as percent control.
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Figure 3-7. E746-A750 del EGFR-expressing HBEC-3KTs require a lowering of
the caspase 9a/9b mRNA ratio to confer anchorage-independent growth (stable
expression). Characterization of HBEC-3KT Δ746 cells stably expressing caspase 9b
shRNA or control shRNA by a) quantitative/competitive RT-PCR analysis of caspase 9
splice variants and b) western blot analysis for protein expression of caspase 9 splice
variants. c) Colony formation assay in soft agar of HBEC-3KT cells stably expressing
caspase 9b shRNA or control shRNA. Depicted is the quantification of the number of
colonies counted, represented as percent control.
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Figure 3-8. E746-A750 del EGFR-expressing HBEC-3KTs require a lowering of
the caspase 9a/9b mRNA ratio to confer anchorage-independent growth (transient
expression). Characterization of HBEC-3KT Δ746 cells transiently expressing caspase
9b shRNA or control shRNA by a) quantitative/competitive RT-PCR analysis of
caspase 9 splice variants and b) western blot analysis for protein expression of caspase
9 splice variants. c) Colony formation assay in soft agar of HBEC-3KT cells transiently
expressing caspase 9b shRNA or control shRNA. Depicted is the quantification of the
number of colonies counted, represented as percent control.
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3.4. Discussion
The PI3-Kinase/Akt pathway is one of the major signaling networks downstream of
EGFR signaling. The presented data has demonstrated that the PI3-Kinase/Akt pathway
regulates the alternative splicing of caspase 9 pre-mRNA in a pro-survival manner, and
that either mutation or overexpression of EGFR in non-transformed human bronchial
epithelial cells (HBEC-3KT) also represses the inclusion of the exon 3,4,5,6 cassette of
caspase 9. Interestingly, the E746-A750 del EGFR-expressing HBEC3-KT cells, which
confer anchorage-independent growth223, demonstrated the greatest effect on lowering the
caspase 9a/9b ratio. This prompted us to investigate the effect of erlotinib, a tyrosine
kinase inhibitor of the human EGFR, on the caspase 9a/9b mRNA ratio. As anticipated,
treatment of A549 cells with erlotinib led to a dose-dependent increase in the caspase 9a/9b
mRNA ratio. We extended these results to show that modulations of the caspase 9a/9b
mRNA ratio regulated the ability of erlotinib to inhibit liquid colony formation of A549
cells.
Based on these findings, and the published evidence that caspase 9a is a tumor
suppressor179, we investigated the effect of modulating the caspase 9a/9b mRNA ratio on
the anchorage-independent growth of the E746-A750 del EGFR-expressing HBEC3-KT
cells.

In parallel, the effect of modulating the caspase 9a/9b mRNA ratio on the

anchorage-independent growth of A549 cells was also examined. The data presented
clearly demonstrates that the alternative splicing of caspase 9 plays a major role in
conferring anchorage-independent growth and in regulating the sensitivity of NSCLC cells
to erlotinib.

CHAPTER 4
THE PI3-KINASE/AKT PATHWAY REGULATES THE ALTERNATIVE
SPLICING OF CASPASE 9 IN A PHOSPHO-SRP30A-DEPENDENT MANNER.

4.1. Introduction
SR proteins are required for constitutive and alternative pre-mRNA processing and
are specific substrates for protein phosphatase-1 (PP1), a ceramide-activated protein
phosphatase. Previous studies from our laboratory demonstrate that endogenous ceramide
modulated the phosphorylation status of SR proteins in a PP1-dependent manner224.
Additionally, our laboratory has recently described a pathway linking the generation of de
novo ceramide and the activation of PP1 to the regulation of the alternative splicing of
caspase-9 pre-mRNA225. Specifically, treatment of A549 lung adenocarcinoma cells with
D-e-C6 ceramide down-regulated the levels of caspase 9b mRNA and immunoreactive
protein coupled with an increase in caspase 9a mRNA and immunoreactive protein levels,
in a dose- and time-dependent manner225.

This effect required the generation of

endogenous ceramide through the de novo pathway and, more importantly, inhibitors of
PP1 abolished the ability of ceramide to affect the alternative splicing of caspase 9225.
Additional studies from our laboratory identified the SR protein, SRp30a, as a critical
splicing factor responsible for regulating the alternative splicing of caspase 9 premRNA226. Furthermore, SRp30a was shown to be a required for ceramide to affect the
77
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alternative splicing of caspase-9 pre-mRNA, thereby linking de novo ceramide generation,
SRp30a, and the regulation of caspase-9 alternative splicing226.
These previous studies from our laboratory prompted us to investigate whether the
phosphorylation status of the RS domain of SRp30a modulated the alternative splicing of
caspase 9 pre-mRNA.

Furthermore, we sought to identify the precise serine residues in

the RS domain of SRp30a which regulated the inclusion/exclusion of the exon 3,4,5,6
cassette of caspase 9 pre-mRNA. Lastly, we examined the role of the phospho-state of
SRp30a on the anchorage-independent growth of A549 lung adenocarcinoma cells.

4.2. Materials and Methods
4.2.1. Cell Culture
A549 cells were grown in 50% RPMI 1640 (Invitrogen Life Technologies,
Carlsbad, CA) and 50% Dulbecco's modified Eagle's medium (Invitrogen Life
Technologies, Carlsbad, CA) supplemented with L-glutamine, 10% (v/v) fetal bovine
serum (Sigma), 100 units/ml penicillin G sodium (Invitrogen Life Technologies, Carlsbad,
CA), and 100 μg/ml streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA).
A549s were purchased from ATCC (Rockville, MD, USA). All cells were maintained at
less than 80% confluency under standard incubator conditions (humidified atmosphere,
95% air, 5% CO2, 37 °C).
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4.2.2. Quantitative/Competitive RT-PCR Quantitative/competitive RT-PCR
Total RNA from cell lines were isolated using the RNeasy® Mini Kit (Qiagen Inc.,
Valencia, CA) according to the manufacturer‘s protocol. Total RNA (1 μg) was reversetranscribed using Superscript III reverse transcriptase (SuperScript™ First-Strand
Synthesis System for RT-PCR, Invitrogen™, Carlsbad, CA) and oligo (dT) as the priming
agent. After 50 min of incubation at 42°C, the reactions were terminated by heating at
70°C for 15 min. Template RNA was then removed using RNase H (Invitrogen, Carlsbad,
CA). To quantitatively evaluate the expression of endogenous caspase 9 splice variants, an
upstream 5‘ primer to caspase-9 (5‘-GCT CTT CCT TTG TTC ATC TCC-3‘) and a 3‘
primer (5‘-CAT CTG GCT CGG GGT TAC TGC-3‘) (Integrated DNA Technologies, Inc.,
Coralville, IA) were used. Using these primers, 20% of the reverse transcriptase reaction
was amplified for 25 cycles (94°C, 30 s melt; 57°C, 30 s anneal; 72°C, 1 min extension)
using Platinum Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA). Gene
products produced from endogenous caspase 9 PCR resulted in a 1248 base pair caspase 9a
splice variant and 798 base pair caspase 9b splice variant. To evaluate the expression of the
splice variant products of the caspase 9 minigene, a 5‘ primer to caspase 9 minigene (5‘CAT GCT GGC TTC GTT TCT G-3‘) and a 3‘ primer (5‘-AGG GGC AAA CAA CAG
ATG G-3‘) were used. Gene products produced from caspase 9 minigene PCR resulted in
an 889 bp caspase 9a splice variant and a 443bp caspase 9b splice variant. Using these
primers, 20% of the reverse transcriptase reaction was amplified for 25 cycles (94°C, 30 s
denaturation; 60°C, 30 s anneal; 72°C, 1 min extension) using Platinum Taq DNA
polymerase (Invitrogen™, Carlsbad, CA). The final PCR products were resolved on a 5%
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TBE acrylamide gel electrophoresis, stained with SYBR® Gold (Invitrogen™, Carlsbad,
CA) and visualized using a Molecular Imager® FX (Bio-Rad) with a 488 nm EX (530 nm
BYPASS) laser.

4.2.3. Western Immunoblotting
Cells were lysed using CelLytic™ lysis Buffer (Sigma-Aldrich) supplemented with
protease Inhibitor cocktail (Sigma-Aldrich). Protein samples (5 μg) were subjected to 10%
SDS-PAGE, transferred to a polyvinylidene difluoride membrane (PDVF) (Bio-Rad) and
blocked in 5% milk/1 X PBS – 0.1% Tween (M-PBS-T) for 2 h. Primary antibodies were
anti-αTubulin (1:1000, Santa Cruz), anti-laminA/C (1:1000, Cell Signaling), and anti-T7
tag (1:10,000, Novagen). Secondary antibodies were HRP-conjugated goat anti-mouse or
anti-rabbit (1:5,000, Sigma-Aldrich). Immunoblots were developed using Pierce enhanced
chemiluminescence (ECL) reagents and Bio-Max film.

4.2.4. Expression plasmids and transient transfections
The mammalian expression vectors pCGT7-SRp30a-WT and the SRp30a RS
domain mutant, SRp30a-RD, were a gift from J.F. Caceres and previously described227.
To generate SRp30a phospho-mutants, site-directed mutagenesis was performed using
QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) according to the
manufacture‘s protocol. To analyzed caspase 9a and caspase 9b mRNA expression, 1.5 x
104 cells were plated into 6-well tissue culture dishes. The following day cells were
transfected with 0.5ug of pCGT7-SRp30a plasmids with or without 0.2ug of caspase 9
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minigene plasmid DNA using Effectene (Qiagen Inc., Valencia, CA) following the
manufacture‘s protocol. Twenty-four hours post-transfection, total RNA was harvested for
RT-PCR analysis.

To analyze the anchorage-independent growth of A549 cells

expressing SRp30a phospho-mutants, 7.5 x 105 cells were plated into 100mm tissue culture
dishes. The following day, cells were co-transfected with 0.5 ug of pEGFP-Endo and 2 ug
of pCGT7-SRp30a constructs using Effectene (Qiagen Inc., Valencia, CA) following the
manufacture‘s protocol.

Twenty-four hours post-plating, cells were sorted using a

Beckman CoulterEPICS Elite ESP multilaser flow cytometer. GFP positive cells were
collected and plated into soft agar (described below) to demonstrate effects on anchorageindependent growth.

4.2.5. Soft agar assays
For soft agar assays,

5,000 GFP positive A549 cells (described above) were

suspended and plated in 0.3% agar (Fisher Scientific) in their appropriate growth media
with all supplements (described above) into 6-well tissue culture plates, and were layered
over a 0.6% agar base in the same media used to suspend cells.

The number of

microscopically visible colonies (>40 cells) were counted 2 weeks later.

4.2.6. In vitro phosphorylation assays
A549 cells (106) were transfected with 2μg of SRp30a-WT, SRp30a-QD, and
SRp30a-QA constructs using Effectene (Qiagen Inc., Valencia, CA) following the
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manufacture‘s protocol. Twenty-four hours after transfection, cells were scraped into 150
uL of NP-40 lysis buffer (50mM Tris-HCL [pH 8.0], 150mM NaCl, 1% NP-40,100ug of
phenylmethyl-sulfonyl fluoride [PMSF]/mL, and protease inhibitor cocktail. The lysates
were incubated with 500 U of alkaline phosphatase (New England Biolabs, Beverly,
Mass.)/mL for 1 hr. at 37ºC. Wild-type and mutant SRp30a proteins were detected by
Western blot using anti-T7 tag antibody (1:10,000).

4.2.7. Subcellular fractionation
A549s cells (106) were transfected with 2μg of pEGFP-Endo, SRp30a-WT,
SRp30a-QD, SRp30a-QA, and SRp30a-RD constructs using Effectene (Qiagen Inc.,
Valencia, CA) following the manufacture‘s protocol. Twenty-four hours after transfection,
cells were washed with PBS and scraped into lysis buffer (20mM HEPES, 1mM EDTA,
2mM MgCl2, 10mM KCl, and 0.25M sucrose) containing protease inhibitor cocktail. Cells
were homogenized with 10 strokes in a douncer and centrifuged for 10 minutes at 1000 x
g. Supernatant was collected as cytosolic fraction and cell pellet was resuspended in lysis
buffer as nuclear fraction.

4.3. Results
4.3.1. The phosphorylation status of SRp30a regulates the alternative splicing of
caspase 9 pre-mRNA.
SR proteins are heavily phosphorylated in their RS domains, and their
phosphorylation status can influence 5‘ splice site selection and exon inclusion (i.e.
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splicing activity) for many pre-mRNAs118,119,134,228,229.

Previously, our laboratory

demonstrated that SRp30a was a required enhancer factor for the inclusion of the exon
3,4,5,6 cassette of caspase 9226. SRp30a was also shown to be required for ceramide to
affect the alternative splicing of caspase 9 pre-mRNA and ceramide treatment led to the
dephosphorylation of SR proteins226. Additionally, SRp30a has been demonstrated to be a
specific target of Akt141,142. Therefore, we hypothesize that the phospho-status of SRp30a
regulates the inclusion of the exon 3,4,5,6 cassette of caspase 9, downstream of Akt
activation. To investigate this hypothesis, we employed an established phospho-mimic of
SRp30a, SRp30a-RD, in which the majority of serine residues in the RS domain were
mutated into aspartic acid227. Co-expression of SRp30a-RD with a functional caspase 9
minigene induced a significant decrease in the caspase 9a/9b ratio compared to wild-type
SRp30a and empty vector controls (Figure 4-1a). Importantly, expression of SRp30a-RD
also induced a significant decrease in the endogenous caspase 9a/9b mRNA ratio as
compared to wild-type SRp30a and empty vector controls (Figure 4-1b).
To determine the serine residue/residues of SRp30a required for regulating the
alternative splicing of caspase 9, site-directed replacement mutagenesis was utilized.
Multiple serine residues in the RS domain of SRp30a contain recognized motifs for Akt
phosphorylation141. These serine residues were individually mutated into aspartic acid to
produce phospho-mimics (see Table 4-1). Co-expression of only the SRp30a-S199D,
SRp30a-S201D, SRp30a-S227D, and SRp30a-S234D mutants with a functional caspase 9
minigene resulted in an decreased caspase 9a/9b ratio compared to wild type SRp30a
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control (Figure 4-1c). Mutation of other serine residues in the RS-domain had no effect on
the ratio of caspase 9a/9b mRNA (see Table 4-1).
We extended these results to produce a SRp30a double phospho-mutant (SRp30aS199,201D), a SRp30a triple phospho-mutant (SRp30a-S199,201,234D), and a SRp30a
quadruple (SRp30a-QD) mutant harboring serine to aspartic acid mutations at residues
199, 201, 227 and 234. Expression of SRp30a double and triple phospho-mutants with the
caspase 9 minigene further decreased the caspase 9a/9b mRNA ratio as compared to the
SRp30a single mutants and SRp30a wild type controls (data not shown). Importantly,
ectopic expression of SRp30a-QD induced a reduction in the caspase 9a/9b ratio
comparable to the SRp30a-RD mutant (Figure 4-1d).

Conversely, a quadruple de-

phospho-mimic of SRp30a (SRp30a-QA) induced the opposite effect in A549 cells (Figure
4-1d). These effects could not be accounted for by localization issues as both SRp30a
quadruple mutants are predominately localized in the nucleus and are expressed in
equivalent amounts, as demonstrated via western blot analysis (Figure 4-1e).
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Table 4-1. Potential phosphorylation sites in SRp30a involved in regulating the
alternative splicing of caspase 9. Listed are the serine residues examined for their role in
regulating the alternative splicing of caspase 9 pre-mRNA. The phosphorylation status of
the corresponding residues were determined by the indicated method and how they
affected the caspase 9a/9b mRNA ratio is depicted.
Possible
phosphosite

Determination

ESI-LC-MS/MS
confirmed

Affect on C9a/C9b
ratio

S199

Mass Spectrometry

Yes

Yes

S201

Mass Spectrometry

Yes

Yes

S205

Mass Spectrometry

Yes

No

S221

Kinase site prediction

No

No

S225

Mass Spectrometry

Yes

No

S227

Mass Spectrometry

Yes

Yes

S231

Mass Spectrometry

Yes

No

S234

Mass Spectrometry

Yes

Yes

S238

Mass Spectrometry

Yes

No

S242

Mass Spectrometry

Yes

No

S244

Mass Spectrometry

Yes

No

S246

Kinase site prediction

No

No

T248

Kinase site prediction

No

No
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Figure 4-1. The phosphorylation status of SRp30a regulates the alternative
splicing of caspase 9 pre-mRNA. a) Quantitative/competitive RT-PCR analysis of
capspase 9 minigene-derived transcripts from A549s co-transfected with the caspase 9
minigene and SRp30a-WT or SRp30a-RD. b) Quantitative/competitive RT-PCR
analysis of endogenous caspase 9 splice variants from A549 cells transfected with
SRp30a-WT or SRp30a-RD. c) Quantitative/competitive RT-PCR analysis of caspase 9
minigene-derived transcripts from A549s co-transfected with the caspase 9 minigene
and the indicated SRp30a phospho-mutants. d) Quantitative/competitive RT-PCR of
endogenous caspase 9 splice variants and the corresponding caspase 9a/9b mRNA
ratios of A549s transfected with SRp30a-QA, SRp30a-QD, or SRp30a-WT. Ratios of
caspase 9a to caspase 9b mRNA were determined by densotimetric analysis of RT-PCR
fragments. e) Western blot analysis of cytosolic and nuclear protien fractions from
A549s transfected with GFP, SRp30a-WT, SRp30a-QD, SRp30a-QA, or SRp30a-RD.
Fractions were analyzed for expression of the T7 tag, lamin, or α-tubulin.
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To demonstrate that these phosphorylation sites are hyperphosphorylated in
NSCLC cells, the phoshorylation status of the transiently expressed epitope-tagged
SRp30a were analyzed by comparing the electrophoretic migration profiles of the proteins
after incubation in the presence of either alkaline phosphatase or denatured alkaline
phosphatase.

Increased migration of SRp30a-WT was observed after treatment with

alkaline phosphatase to levels corresponding to those of SRp30a-QD and SRp30a-QA after
treatment with denatured alkaline phosphatase, indicating that serine 199, 201, 227, and
234 exist in a phosphorylated state in A549 cells (Figure 4-2).

4.3.2. The phosphorylation status of SRp30a modulates the effect of Akt signaling on
alternative splicing of caspase 9.
Blaustein and co-workers recently provided evidence for a direct involvement of
Akt in modifying SRp30a activity141. To determine whether the PI3-Kinase/Akt pathway
regulates the alternative splicing of caspase 9 in a phospho-SRp30a-dependent manner,
SRp30a-QD was expressed in the presence or absence of the Akt inhibitor, AKT VIII. In
the presence of SRp30a-QD, AKT VIII inhibitor was unable to return/increase the ratio of
the caspase 9a/9b mRNA to the same extent as compared to wild-type SRp30a. This effect
was specific for the SRp30a-QD mutant as co-expression of either the empty vector or
SRp30a wild-type vector had no effect on the ability of this inhibitor to increase the
caspase 9a/9b mRNA ratio (Figure 4-3). Therefore, the Akt pathway regulates the
alternative splicing of caspase 9 at least partially via the phospho-state of SRp30a.
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WT

QD

QA

SRp30a

T7 tag

Figure 4-2. Serine residues 199, 201, 227, and 234 of SRp30a exist in a hyperphosphorylated state in A549 cells. Immunoblot analysis of the phosphorylation state
of SRp30a-WT and the SRp30a phospho-mutants. A549s were transfected with the
indicated T7-tagged SRp30a constructs, total cell lysates were incubated in the
presence of either active alkaline phosphatase (AP) or denatured alkaline phosphatase
(den AP), and tagged SRp30a was detected by Western blotting.
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Figure 4-3. The phosphorylation status of SRp30a modulates the effect of Akt
signaling on the alternative splicing of caspase 9. a) Quantitative/competitive RTPCR analysis of endogenous caspase 9 splice variants and their corresponding caspase
9a/9b mRNA ratios from A549s transfected with SRp30a-WT or SRp30a-QD in the
presence or absence of AKT inhibitor VIII [25μM]. Ratios of caspase 9a to caspase 9b
mRNA were determined by densotimetric analysis of RT-PCR fragments. b) Graphical
depiction of the caspase 9a/9b mRNA ratios.
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4.3.3. The phosphorylation status of SRp30a regulates the anchorage-independent
growth of A549 cells.
Our above findings indentify SRp30a as a critical RNA trans-factor regulating the
alternative splicing of caspase 9 in a phosphorylation-dependent manner. Specifically, the
phosphorylation status of serine 199, 201, 227, and 234 of SRp30a was demonstrated to
modulate the caspase 9a/9b mRNA ratio. Importantly, these serine residues were predicted
to be EGF stimulated as reported by PHOSIDA, a phosphorylation site database, and
Human Protein Reference Database (HPRD). Based on this knowledge, and our findings
that the E746-A750 del EGFR-expressing HBEC-3KT cells require a lowering of the
caspase 9a/9b mRNA to confer anchorage-independent growth (discussed in chapter 3), we
hypothesized that the phospho-status of SRp30a at serine 199, 201, 227, and 234 regulates
the anchorage-independent growth of A549 cells.

To test this hypothesis, A549s were

transiently transfected with GFP-vector control, SRp30a-QD, and SRp30a-QA, and
analyzed for their ability to grow in soft agar. Indeed, expression of SRp30a-QD resulted
in significantly more colonies in soft agar as compared to A549s expressing SRp30a-QA
or GFP-vector control (Figure 4-4). Conversely, expression of SRp30a-QA resulted in
significantly fewer colonies in soft agar as compared to A549s expressing SRp30a-QD or
GFR-vector control (Figure 4-4). Thus, the phosphorylation status of serine residues 199,
201, 227, and 234 of SRp30a plays an important role in the anchorage-independent growth
of A549 cells.

Percent control
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Figure 4-4. The phosphorylation status of SRp30a regulates the anchorageindependent growth of A549 cells. A549 cells transiently expressing GFP-vector
control, SRp30a-QD, or SRp30a-QA were assayed for their ability to grow in soft agar.
Cells were allowed to grow for two weeks before colonies were counted. Depicted is
the quantification (mean
s.d.) of the number of colonies counted, represented as
percent control.

4.4. Discussion
The functional role of the RS domain of SR proteins in constitutive and alternative
splicing has been extensively studied.

Published reports have demonstrated that RS

domains do not contribute to the protein‘s affinity for pre-mRNAs230-232 but instead directs
protein-protein interactions, functioning as activators of RNA splicing124,233.
Initial studies presented in this chapter demonstrate that expression of an
established phospho-mimic of SRp30a, SRp30a-RD, repressed the inclusion of the exon
3,4,5,6 exon cassette of caspase 9 pre-mRNA. The majority of the serine residues in the
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RS domain of SRp30a-RD were previously mutated into aspartic acid227.

Published

reports with SRp30a-RD demonstrated in vitro that the RS domain of this mutant could
mimic the structural and functional properties of a naturally phosphorylated RS domain
that are required for RNA splicing227.
These initial results were extended to identify the specific serine residues in the RS
domain of SRp30a that regulated the inclusion/exclusion of the exon 3,4,5,6 cassette of
caspase 9 pre-mRNA. Specifically, the phospho-status of serine residues 199, 201, 227,
and 234 of SRp30a were demonstrated to modulate the effect of Akt signaling on the
alternative splicing of caspase 9. These data are consistent with published findings by
Blaustein and colleagues who have recently provided evidence for Akt directly
phosphorylating SRp30a141. Similarly, Cooper and colleagues have presented strong data
demonstrating translocation of Akt2 to the nucleus in response to insulin or IGF-1 and
subsequent phosphorylation of the SR protein, SRp40, which closely resembles SRp30a142.
Thus, we propose the predominantly expressed Akt isoform translocates to the nucleus and
phosphorylates SRp30a at specific regulatory residues leading to the exclusion of the exon
3,4,5,6 cassette from caspase 9 mRNA. Lastly, studies presented in this chapter
demonstrate that the phosphorylation status of serine residues 199, 201, 227, and 234 of
SRp30a were also important in modulating the anchorage-independent growth of A549s.

CHAPTER 5
REGULATION OF THE ALTERNATIVE SPLICING OF BCL-X IN A549 LUNG
ADENOCARCINOMA CELLS.

5.1. Introduction
Numerous studies have shown that overexpression of Bcl-x(L) in cells confers
resistance to many apoptotic stimuli, and cooperates with oncogenic factors (e.g. c-Myc) in
tumorigenesis180,181,184-191. Furthermore, many cell types spontaneously resistant to
chemotherapeutic agents also demonstrate increased levels of Bcl-x(L)192-197.

The

regulation of Bcl-x(L) expression is a complex mechanism consisting of both
transcriptional and post-transcriptional processes. In regards to post-transcriptional
processing, the BCL-x gene, via alternative 5‘ splice site selection within exon 2, produces
either the pro-apoptotic Bcl-x(s) (upstream 5‘SS selection) or the anti-apoptotic Bcl-x(L)
(downstream 5‘SS selection). Several studies have demonstrated that the Bcl-x splice
variant, Bcl-x(s), in contrast to Bcl-x(L), promotes apoptosis181,198-201, and the mechanism
of alternative 5‘ splice site selection of Bcl-x pre-mRNA has emerged as a potential target
for anti-cancer therapeutics in non-small cell lung cancer (NSCLC). Specifically, Taylor
and co-workers showed that Bcl-x alternative splicing was specifically modulated using an
antisense oligonucleotide specific for Bcl-x pre-mRNA at a site surrounding the Bcl-x(L)
5‘ splice site234. Hybridization of this oligonucleotide to Bcl-x pre-mRNA induced an
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increase in the expression of Bcl-x(s) and a decrease in the expression of Bcl-x(L) resulting
in sensitization of the NSCLC cells to chemotherapeutic agents and eventually inducing
apoptosis after long term exposure (> 48 hr)234. These findings were also demonstrated by
Kole and co-workers who also translated these findings to several different cancer types235.
Thus, regulation of the 5‘SS selection within the Bcl-x exon 2 is a critical factor in
determining whether a NSCLC cell is susceptible or resistant to apoptosis in response to
chemotherapy234-238.
To this end, previous studies by our laboratory defined the generation of de novo
ceramide and the activation of protein phosphatase-1 (PP1) as major components of an
apoptotic signaling pathway regulating the 5‘ splice site selection of Bcl-x exon 2 in
response to chemotherapeutic agents224,225.

A recent study by Zhou and co-workers

verified these early findings and extended the list of chemotherapeutic agents to emetine, a
potent protein synthesis inhibitor239. Mechanistic studies from our laboratory identified the
ceramide-responsive RNA cis-element 1 (CRCE 1) located in exon 2 of Bcl-x pre-mRNA
277-295 bp upstream from intron 2240. In further mechanistic studies, the involvement of
the splicing factor, SAP155, as an RNA trans-factor that interacted with CRCE 1 and
regulated the 5‘SS selection of Bcl-x pre-mRNA was elucidated241. Importantly, this RNA
trans-factor was required for the effect of ceramide on the alternative 5‘SS selection of
Bcl-x, and downregulation of SAP155 by siRNA technology was as effective as ceramide
in reducing the viability of NSCLC cells241.
In this regard, we demonstrate that the ratio of Bcl-x(L)/(s) mRNA is increased in a
large number of NSCLC tumors. Based in these findings, the goal of these studies was to
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examine survival/mitogenic pathways responsible for regulating the alternative 5‘SS
selection of Bcl-x pre-mRNA in malignant NSCLC cells. Specifically, we identify the PI3
kinase pathway as a key survival pathway regulating the alternative 5‘SS selection of Bcl-x
pre-mRNA to produce the anti-apoptotic Bcl-x(L) isoform. Furthermore, we show that
PKCη is downstream of PI3 kinase and regulates this alternative splicing mechanism via the
expression of SAP155. Overall, this report defines the survival/oncogenic pathway
regulating the alternative splicing of Bcl-x pre-mRNA in A549 lung adenocarcinoma cells.

5.2. Materials and Methods
5.2.1. Cell Culture
A549 cells were grown in 50% RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA)
and 50% Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Carlsbad,
CA) supplemented with L-glutamine, 10% (v/v) fetal bovine serum (Sigma), 100 units/ml
penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). A549s were purchased
from ATCC (Rockville, MD, USA). Cells were maintained at less than 80% confluency
under standard incubator conditions (humidified atmosphere, 95% air, 5% CO2, 37 °C).

5.2.2. Quantitative/Competitive RT-PCR
Total RNA from cell lines were isolated using the RNeasy® Mini Kit (Qiagen Inc.,
Valencia, CA) according to the manufacturer‘s protocol. Total RNA (1 μg) was reversetranscribed using Superscript III reverse transcriptase (SuperScript™ First-Strand
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Synthesis System for RT-PCR, Invitrogen™, Carlsbad, CA) and oligo (dT) as the priming
agent. After 50 min of incubation at 42°C, the reactions were terminated by heating at
70°C for 15 min. Template RNA was then removed using RNase H (Invitrogen, Carlsbad,
CA). The primers used to evaluate Bcl-x splice variants were (5‘-GAG GCA GGC GAC
GAG TTT GAA-3‘) and (5‘-TGG GAG GGT AGA GTG GAT GGT-3‘) (Integrated DNA
Technologies, Inc., Coralville, IA). The PCR conditions for analyzing the expression of
Bcl-x splice variants were 95ºC for 5 mins followed by 25 cyles of 94ºC for 30s, 58ºC for
30s and 72ºC for 1min using Platinum Taq DNA polymerase (Invitrogen Life
Technologies, Carlsbad, CA). The final PCR products were resolved on a 5% TBE
acrylamide gel electrophoresis, stained with SYBR® Gold (Invitrogen™, Carlsbad, CA)
and visualized using a Molecular Imager® FX (Bio-Rad) with a 488 nm EX (530 nm
BYPASS) laser.

5.2.3. Western Immunoblotting
Cells were lysed using CelLytic™ lysis Buffer (Sigma-Aldrich) supplemented with
protease Inhibitor cocktail (Sigma-Aldrich). Protein samples (5 μg) were subjected to 10%
SDS-PAGE, transferred to a polyvinylidene difluoride membrane (PDVF) (Bio-Rad) and
blocked in 5% milk/1 X PBS – 0.1% Tween (M-PBS-T) for 2 h. Primary antibodies were
anti-PKCη (1:1,000, Santa Cruz), anti-PKCδ (1:1,000, Santa Cruz), anti-Sap155 (1:1,000),
and anti-β-actin (1:5,000, Sigma-Aldrich). Secondary antibodies were HRP-conjugated
goat anti-mouse or anti-rabbit (1:5,000, Sigma-Aldrich). Immunoblots were developed
using Pierce enhanced chemiluminescence (ECL) reagents and Bio-Max film.
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5.2.4. Silence interfering RNA transfection
For inhibition of PKCη and PKCδ expression, cell lines were transfected with either
PKCη SMARTpool multiplex, PKCδ SMARTpool multiplex, or scrambled control siRNA
(Dharmacon; Lafayette, CO) using Dharmafect 1 transfection reagent (Dharmacon;
Lafayette, CO) following the manufacturer‘s protocol. Briefly, cell lines were plated in sixwell tissue culture dishes and allowed to rest overnight. At 50% confluence, cells were
transfected with siRNA [100nM] using Dharmafect 1 in Opti-Mem I reduced-serum
medium. Forty-eight hours post-transfection, RNA and/or protein were isolated.

5.2.5. Inhibitor studies
For Inhibitor studies, 1.2 x 105 A549 cells were plated into 6-well tissue culture
plates. The following day media was removed and replaced with the appropriate complete
growth media.

Cells were subsequently treated with sham control (1:1000) or the

appropriate concentration of active inhibitor (1:1000) (Calbiochem). Twenty-four hours
post-treatment, total RNA and/or protein was isolated.

5.3. Results
5.3.1. The alternative splicing of Bcl-x is dysregulated in a variety of NSCLC tumors.
Previously, our laboratory had demonstrated that the alternative splicing of Bcl-x
pre-mRNA was regulated by apoptotic stimuli

242,243

. In this study, we expanded our

investigations to test the hypothesis that the alternative splicing of Bcl-x was dysregulated
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(in a pro-survival manner or increased Bcl-x(L)/(s) mRNA ratio) in cancer phenotypes,
specifically NSCLC tumors. Utilizing total RNA samples from pathologist-verified human
NSCLC tumor samples, quantitative/competitive RT-PCR analysis was performed to
determine the degree of dysregulation in the Bcl-x(L)/(s) ratio as compared to normal lung
tissue controls. Tumor samples were categorized into three groups respectively: normal, a
Bcl-x(L)/(s) mRNA ratio < 5.8; moderately dysregulated, a Bcl-x(L)/(s) mRNA ratio of
5.8-7.3; and highly dysregulated, a Bcl-x(L)/(s) mRNA ratio > 7.3 (Figure 5-1). These
classifications regarding the degree of dysregulation were due to the observation that the
normal lung tissue samples had a Bcl-x(L)/(s) ratio of 4.75 ± 0.15 (N=4). Of the NSCLC
tumors examined, 70% (N=47) presented with a > 25% increase in the Bcl-x(L)/(s) mRNA
ratio as compared to normal lung tissue controls. Even more dramatic, 27% of NSCLC
tumors examined presented with a > 50% increase in the Bcl-x(L)/(s) mRNA ratio (Figure
5-1). Thus, the ratio of Bcl-x(L)/(s) mRNA is dramatically increased in a high percentage
of NSCLC tumors correlating with an increase in the oncogenic cooperating factor, Bclx(L). Therefore, these data indicate that a significant portion of lung adenocarcinoma
tumors demonstrate dysregulated alternative splicing of Bcl-x favoring a pro-survival/prooncogenic phenotype.
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Figure 5-1. The Bcl-x(L)/(s) mRNA ratio is dysregulated in NSCLC tumors. A
population of cDNAs from pathologist-verified lung adenocarcinomas, squamous cell
carcinomas, and large cell carcinomas (Origene; Rockville, MD) underwent
quantitative/competitive PCR for expression of Bcl-x splice variants.
a)
Representation of the RT-PCR analysis used to determine the degree of Bcl-x(L)/(s)
dysregulation in NSCLC tumor samples where N is normal lung tissue and T is tumor
tissue. b) Quantitative/competitive PCR analysis of Bcl-x splice variants demonstrate
that 43% of NSCLC tumors present a moderately dysregulated Bcl-x(L)/(s) mRNA
ratio (Bcl-x(L)/(s) ratio of 5.9-7.3) and 27% of NSCLC tumors present a highly
dysregulated Bcl-x(L)/(s) mRNA ratio (Bcl-x(L)/(s) ratio >7.3) (N=47), as determined
by densitometric analysis of PCR products.
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5.3.2. The PI3-Kinase pathway regulates the 5’ splice site selection of Bcl-x premRNA.
Previously, our laboratory has demonstrated that increases in endogenous ceramide
levels via the de novo sphingolipid pathway regulates the alternative splicing of Bcl-x premRNA resulting in a decrease in the Bcl-x(L)/(s) mRNA ratio225. In this study, we
hypothesized that one of the major survival/mitogenic pathways regulates the alternative
processing of Bcl-x pre-mRNA to favor the production of anti-apoptotic Bcl-x(L), thereby
increasing the Bcl-x(L)/(s) mRNA ratio. To investigate this hypothesis, these pathways
were examined for regulation of the alternative splicing of Bcl-x pre-mRNA utilizing
small-molecule inhibitors well-characterized in the scientific literature. Treatment of A549
cells with the following inhibitors, the MAP Kinase inhibitor PD 98059 [10μM], MEK 1/2
inhibitor U0126 [10μM], Rho-kinase inhibitor Y-27632 [10μM], Casein Kinase II inhibitor
DMAT [10μM], and Src kinase inhibitor [25μM] had no effect on the alternative splicing
of Bcl-x pre-mRNA. In contrast, treatment of A549 lung adenocarcinoma cells with the
PI3-Kinase inhibitor LY294002 [50 μM] resulted in a significant reduction in the ratio of
Bcl-x(L)/(s) splice variants compared to the inactive, structurally related compound,
LY303511 [50μM] (Figure 5-2). Specifically, the Bcl-x(L)/(s) mRNA ratio decreased
from 6.00  0.16 for LY303511 control-treated samples to 3.40  0.19 for LY294002treated samples (p < 0.01; n=6), corresponding to approximately a ~45% decrease in the
Bcl-x(L)/(s) mRNA ratio. Therefore, these data demonstrate that PI3-Kinase regulates the
alternative splicing of Bcl-x pre-mRNA in an anti-apoptotic/pro-survival manner.
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Figure 5-2. Effect of PI3-Kinase inhibiton on the alternative splicing of Bcl-x premRNA. Quantitative/competitive RT-PCR analysis of Bcl-x splice variants and the
corresponding Bcl-x(L)/(s) mRNA ratios from A549s treated with either structurally
inactive LY303511 [50μM] or LY294002 [50μM]. The ratio of Bcl-x(L) to Bcl-x(s)
mRNA was determined by densitometric analysis of RT-PCR fragments (p<0.01, N=6).
Data are expressed as means
s.d. Data are representative of three separate
determinations on two separate occasions.

5.3.3. PKCι regulates the activation of the Bcl-x(s) 5’ splice site in A549 cells.
Akt/PKB, aPKCs (ξ andη), mTOR/S6 kinase, and PKCδ are downstream of
PI3Kinase, all of which have been well-described in the literature. To investigate the
downstream effector of PI3-Kinase responsible for regulating the alternative splicing of
Bcl-x pre-mRNA, well-characterized small-molecule inhibitors and RNAi technology were
employed. Treatment of A549 cells with either the small-molecule Akt1/2 inhibitor, AKT
VIII [25μM], the classical PKC (cPKC) inhibitor, GF109203X [10μM], the cPKC/novel
PKC (nPKC) inhibitor, Gö6976 [10μM], or the mTOR/S6 kinase inhibitor, rapamycin
[10μM], had no effect on the Bcl-x(L)/(s) mRNA ratio. On the other hand, treatment of
A549 cells with the pan-Protein Kinase C (cPKCs, nPKCs, and atypical PKCs) inhibitor
Gö6983 [10 μM] (Figure 5-3), significantly decreased the Bcl-x(L)/(s) mRNA ratio from
6.04  0.18 for control samples to 3.16  0.29 (p<0.05; n=6). The effects were specific to
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the 5‘SS selection of Bcl-x pre-mRNA as the alternative splicing of caspase 9, another de
novo ceramide target, was unaffected by Gö6983. Therefore, these data demonstrate that
the PI3-Kinase survival pathway regulates the alternative splicing of Bcl-x via an atypical
PKC.
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Figure 5-3. Inhibition of PKCs decreases the Bcl-x(L)/(s) mRNA ratio in A549
cells. Quantitative/competitive RT-PCR analysis of Bcl-x splice variants and the
corresponding Bcl-x(L)/(s) mRNA ratios from A549s treated with either 0.1% DMSO
or Gö6983 [10μM]. The ratio of Bcl-x(L) to Bcl-x(s) mRNA was determined by
densitometric analysis of RT-PCR fragments (p<0.01, N=6). Data are expressed as
means s.d. Data are representative of three separate determinations on two separate
occasions.

The results obtained with the small molecule inhibitors demonstrated that an aPKC
was involved in regulating the alternative splicing of Bcl-x pre-mRNA. Specifically, the
PKC inhibitors, Gö6976 & GF109203X, are effective toward cPKCs, nPKCs, and
PKD/PKCµ, but had no effect on the alternative splicing of Bcl-x pre-mRNA. In contrast,
the pan-PKC inhibitor Gö6983 was very effective in lowering the Bcl-x(L)/(s) mRNA
ratio. In contrast to both Gö6976 & GF109203X, Gö6983 also inhibits atypical PKCs.
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Therefore, process of elimination suggested that an aPKC regulated the 5‘SS selection of
Bcl-x pre-mRNA. To confirm a role for an aPKC in this mechanism, siRNA to both human
aPKC isoforms, PKCη and PKCδ, was employed. In contrast to PKCδ, Downregulation of
PKCη, a known downstream target of the PI3-Kinase, induced the activation of the Bcl-x(s)
5‘SS, decreasing the Bcl-x(L)/(s) ratio from 6.12 ± 0.12 for DMSO-treated cells to 4.01 ±
0.11 for siPKCη-treated cells (Figure 5-4a). Thus, the atypical PKC, PKCη, regulates the
alternative splicing of Bcl-x pre-mRNA in a pro-survival fashion.
Our laboratory has previously reported that the RNA trans-factor, SAP155,
regulates the 5‘ splice site selection of Bcl-x pre-mRNA. To determine whether the
expression of SAP155 was a distal mechanism regulated by PKCη, siRNA to PKCη was
again employed to examine the expression of SAP155. Knockdown of PKCη by siRNA
induced a significant decrease in the levels of SAP155 (Figure 5-4b). These data provide
preliminary evidence for PKCη regulation of the 5‘SS selection of Bcl-x pre-mRNA via
upregulation of SAP155.
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Figure 5-4. Downregulation of PKCι decreases the Bcl-x(L)/(s) mRNA ratio and
correlates with a downregulation of Sap155 protein expression in A549 cells.
Quantitative/competitive RT-PCR analysis of Bcl-x splice variants and the
corresponding Bcl-x(L)/(s) mRNA ratios from A549s transfected with control siRNA or
PKCη siRNA. Knockdown of PKCη was confirmed by western blot. The ratio of Bclx(L) to Bcl-x(s) mRNA was determined by densitometric analysis of RT-PCR
fragments (p<0.01, N=6). Data are expressed as means s.d. b) Total proteins from
A549s transfected with the indicated siRNAs were also subjected to western blot
analysis to determine expression of SAP155.
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5.4. Discussion
The presented study began from our first observation that the alternative splicing of
Bcl-x pre-mRNA was dysregulated in a large percentage of transformed lung epithelial
cells. This led to the hypothesis that a survival pathway of signal transduction regulated the
alternative splicing of Bcl-x pre-mRNA. Indeed, we have previously shown that a
contrasting pathway in apoptotic signaling existed for the activation of the Bcl-x(s) 5‘
splice site. Specifically, our laboratory showed that the production of Bcl-x(s) via
alternative splicing was dependent on the generation of de novo ceramide and the
activation of PP1

242,244

. Therefore, a survival pathway regulating this key distal

mechanism and balancing the cell between apoptosis and survival was likely to exist as
well. The data presented demonstrates that the atypical PKC, PKCη, is a major regulator of
the alternative splicing of Bcl-x pre-mRNA in A549 cells, acting downstream of the major
survival/oncogenic pathway, PI3-Kinase. Therefore, in contrast to published reports
demonstrating a classical PKC responsible for regulating the 5‘ SS selection of Bcl-x premRNA in non-malignant cells245, it is an oncogenic atypical PKC that regulates the 5‘SS
selection in a pro-survival fashion in transformed phenotypes.
Once the upstream components in the survival signaling pathway were determined,
our laboratory focused on linking these upstream signals to downstream RNA trans-factors
known to modulate the 5‘ splice site selection of Bcl-x pre-mRNA. For this purpose, we
turned to the literature as well as our own work for these RNA trans-factors. In a
collaboratory study with Sette and co-workers, SAM68, a well established RNA transfactor with roles in cell signaling and transformation, was shown to regulate the 5‘ splice
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site selection in HEK293 cells. However, this finding did not translate to non-small cell
lung cancer cells, as siRNA directed against SAM68 only slightly inhibited the use of the
Bcl-x(s) 5‘ splice site246.
From the negative results obtained on SAM68, we then examined the expression of
the RNA trans-factor, SAP155. Our laboratory has previously reported this RNA transfactor functioning as a repressor of the the Bcl-x(s) 5‘ splice site241. The data presented in
this chapter provides a preliminary link between the expression of SAP155 to the
activation/expression of the NSCLC proto-oncogene, PKCη. As to how PKCη regulates the
expression of SAP155 is currently unknown.
As stated in the introduction of this chapter, the physiological significance of the
Bcl-x(L)/Bcl-x(s) mRNA ratio has been documented by many reports in the literature
demonstrating that the fate of the cell can be determined by the proportion of anti-apoptotic
Bcl-x(L) to pro-apoptotic Bcl-x(s)

181,247,248

. Furthermore, the induction of pro-apoptotic

Bcl-x(s) has also been shown to sensitize cells to apoptosis and loss of viability to
chemotherapeutic agents

247,248

. Published findings from our laboratory corroborate these

findings demonstrating that treatment of A549 cells with concentrations of ceramide
known to activate the Bcl-x(s) 5‘ splice site also lowered the IC50 of the chemotherapeutic
agent, daunorubicin

242

.

Taken together, these data suggest a link between signal

transduction pathways mediating the 5‘ splice site selection of Bcl-x pre-mRNA and the
sensitivity of cells to apoptosis in response to chemotherapeutics. Specifically, SAP155
expression may be a key link, as we have previously shown that ceramide could not induce
apoptosis or sensitize cells to daunorubicin in A549 cells above the extent of SAP155
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downregulation by siRNA. Unfortunately, little is known about the PKCη signaling
pathway to form a strong hypothesis as to how ceramide may be blocking signals
mediating SAP155 expression. The activation of the Bcl-x(s) 5‘SS is regulated by a
serine/threonine protein phosphatase. Therefore, it is conceivable that a ceramide-activated
protein phosphatase such as PP1 may dephosphorylate PKCη effectively ―shutting-down‖
the pro-survival pathway and thus, SAP155 expression.
Outside of the realm of chemotherapy sensitive, the alternative splicing of Bcl-x
pre-mRNA may also have roles in oncogenesis. Recently, Evan and co-workers
demonstrated that Bcl-x(L) cooperated with c-Myc in oncogenic transformation in vivo188.
These findings correlate well to the observation that a large number of NSCLC tumors
demonstrated dysregulation of the alternative 5‘SS selection of Bcl-x exon 2 to favor Bclx(L) expression. Therefore, PKCη may act as an oncogene via simple removal of Bcl-x(s)
with concomitant increase in Bcl-x(L), which promotes oncogenesis.
In conclusion, this study demonstrates several novel findings. First, this study
demonstrates that the PI3-Kinase/PKCη pathway regulates the alternative 5‘SS selection of
Bcl-x exon 2. Second, this study provides preliminary data that the proto-oncogene PKCη
regulates this distal mechanism via upregulation of SAP155. Therefore, this study provides
a key distal signaling mechanism regulated by a proto-oncogene for NSCLC and provides
a plethora of new targets for the development of therapeutics to combat NSCLC.

CHAPTER 6
GENERAL DISCUSSION

RNA splicing is an essential, precisely regulated process and, its regulation has
been demonstrated to play a critical role in human disease202.

Research has clearly

demonstrated that dysregulation of cell signaling pathways has a significant impact on
alternative RNA splicing in human pathologies, including cancer249-251. In this study, the
oncogenic signaling pathways regulating the alternative splicing of caspase 9 and Bcl-x in
NSCLC were examined. The molecular mechanisms regulating the alternative splicing of
Bcl-x were thoroughly discussed in chapter 5. Therefore, this chapter will focus on
discussing the molecular mechanisms regulating the alternative splicing of caspase 9 and
their relevance to our current understanding of NSCLC.
The presented study demonstrates several important and novel findings and begins
to clarify the complex mechanism regulating the alternative splicing of caspase 9 as well as
impacts the mounting data as to clinical relevance. As to the latter, the study begins by
demonstrating that the alternative splicing of caspase 9 is dysregulated in a large majority
of NSCLC cell lines and tumors, including adenocarcinomas, squamous cell carcinomas,
and large cell carcinomas. More importantly, the presented study also demonstrates the
intriguing finding that a key oncogenic factor in NSCLC, EGFR overexpression/mutation,
regulates this splicing mechanism. The significance of this finding stems from the
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knowledge that EGFR mutation occurs in a large percentage of NSCLCs, roughly 10%.
Furthermore, EGFR mutation is also considered an early event in the development of
NSCLC, since the mutation is also found in normal epithelial cells prior to metaplasia and
adenoma formation, enhancing the hypothesis that the alternative splicing of caspase 9
plays a role in early events leading to the formation of NSCLC. Importantly, overexpressed
EGFR, along with its ligands, occur in approximately 70% of NSCLCs. In this regard, this
study also demonstrates that the PI3-Kinase/Akt pathway is downstream of the EGFR
mutation/overexpression and upstream of the alternative splicing of caspase 9. Again, this
makes logical sense in relation to cellular transformation as this pathway is found
constitutively active in approximately 58% of NSCLC cell lines and tumors69,70. This
pathway is also linked to constitutive EGFR activity, NF-θB activation, and the ability of
oncogenic ras to transform various cell types. More importantly in a therapeutic sense, Akt
activity correlates with patient survival after treatment with agents targeting EGFR (e.g.
gefitinib). Furthermore, Akt inhibitors have been shown to circumvent the resistance of
cells to gefitinib acquired from the T790M EGFR mutation. Thus, the Akt pathway
activated by the EGFR receptor is extremely important in a therapeutic sense, and this
study further shows that this activation of Akt is distinctly different from the Akt pathway
activated by oncogenic Ras.
Clinical relevance is further enhanced by our findings with the EGFR inhibitor,
erlotinib (e.g. Tarceva™). The treatment of NSCLC cells with this compound increased the
caspase 9a/9b mRNA ratio to a more normal presentation. More importantly, genetic
manipulation of the alternative splicing of caspase 9 had profound effects on the sensitivity
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of NSCLC cells to this chemotherapy. Ectopic expression of caspase 9b essentially
produced NSCLC cells completely resistant to erlotinib at concentrations 4-times the IC50
as compared to control cells. As erlotinib has shown promise in clinical trials by
significantly improving the survival rate of NSCLC patients, examining the alternative
splicing of caspase 9 may have future prognostic value for a subset of patients.
A role for EGF/PI3-Kinase/Akt signaling in regulating the alternative splicing of
caspase 9 in a pro-oncogenic manner is also interesting due to the links between Akt
signaling and the modulation of RNA trans-factors of the SR protein family. For example,
a collaboratory study with Cooper and co-workers demonstrated that Akt2 regulated the
alternative splicing of protein kinase CβII pre-mRNA via phosphorylation of the SR
protein family member, SRp40142. Furthermore, a recent publication by Blaustein and coworkers demonstrated that Akt could phosphorylate SRp30a directly in cells, and the
serines 199, 201, 227, and 234 were among those identified141. Based on the
aforementioned reports, the direct phosphorylation of SRp30a by Akt could occur either in
the nucleus or in the cytoplasm. For example, Akt has been known to translocate to the
nucleus upon activation by certain stimuli where the enzyme could phosphorylate the RNA
trans-factor. Conversely, SRp30a is localized almost exclusively in the nucleus upon
phosphorylation due to shuttling, and thus activated Akt may also phosphorylate the RNA
trans-factor in the cytoplasm and induce the translocation of SRp30a to the nucleus,
compete with dephosphorylated SRp30a, and repress the inclusion of the exon 3,4,5,6
cassette of caspase 9 pre-mRNA. Cooper and co-workers have in recent years proposed an
analogous mechanism as to the former presenting strong data that Akt2 translocates to the
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nucleus in response to insulin or IGF-1 to phosphorylate the RNA trans-factor, SRp40,
which is closely-related to SRp30a142. Thus, we propose that EGF induces the activation
and translocation of the predominantly expressed Akt isoform to the nucleus/nuclear
membrane, which phosphorylates SRp30a at specific regulatory residues leading to the
exclusion of the exon 3,4,5,6 cassette from caspase 9 mRNA (Figure 6-1).
A hyper-phosphorylated SRp30a affecting the inclusion/exclusion of exons is in
line with reports in the literature on the functionality of this RNA trans-factor. For
example, Manley and co-workers demonstrated that phosphorylation of SRp30a did not
affect the ability of the RNA trans-factor to bind to a specific RNA cis-element, but hyperphosphorylation did inhibit the ability of SRp30a to recruit other RNA trans-factors
required for the role of this protein in modulating alternative splicing cascades133. Thus,
hyper-phosphorylation of SRp30a by Akt would likely inhibit the ability of this RNA
trans-factor to recruit other spliceosomal components and enhance the inclusion of the
exon 3,4,5,6 cassette of caspase 9. This study completely supports these early findings of
Manley and co-workers and suggests that a hyperphosphorlated SRp30a on serines 199,
201, 227, and 234, and possibly other unidentified sites by Akt, is incompetent as an
activator of the inclusion of the exon 3,4,5,6 cassette of caspase 9.
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Figure 6-1. The alternative splicing of caspase 9 is regulated by the EGFR/PI3Kinase/Akt pathway in a phospho-SRp30a-dependent manner. Following EGFR
stimulation, PI3Kinase becomes activated and in turn, generates specific inositolphospholipids that are recognized by Akt. Akt then translocates to the membrane
through binding of its PH-domain and becomes activated. Akt is then released to
perform both cytosolic and nuclear functions. It is unclear whether Akt modifies
SRp30a in the nucleus or the cytoplasm, or if Akt phosphorylates SRp30a directly or
indirectly. Phosphorylated SRp30a, specifically on serine residues 199, 201, 227, and
234, then functions to repress the inclusion of the exon 3,4,5,6, cassette of caspase 9,
favoring the production of caspase 9b mRNA. We hypothesize when SRp30a is
phosphorylated, steric hindrance prevents the association of key binding partners such.
However, non-phosphorylated SRp30a is able to associate with key binding partners,
allowing it to enhance inclusion of the exon 3,4,5,6, cassette of caspase 9, favoring the
production of caspase 9a.
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Indeed, a preliminary search of the Splicing Rainbow database252 predicts multiple RNA
cis-elements for SRp30a within the exon 3,4,5,6 cassette of caspase 9, possibly explaining
the major role that SRp30a plays in mediating the inclusion of this exon cassette.
Interestingly, the phospho-state of SRp30a in regulating the inclusion/exclusion of the
exon 3,4,5,6 cassette also ―fits‖ well with our previous findings that ceramide induced both
the dephosphorylation of SR proteins (including SRp30a) and the inclusion of the caspase
9 exon cassette favoring caspase 9a expression226. Furthermore, our laboratory
demonstrated that SRp30a was required for ceramide effects on the inclusion of the exon
cassette. Thus, a dephosphorylated SRp30a correlates with exon inclusion and enhanced
complex formation. Based on our previous results and results presented in this study, this
mechanism of SRp30a phospho-status and the alternative splicing of caspase 9 may be a
key distal point by which ceramide acts as a tumor suppressing/cell senescence agent.
Ceramide signaling and the PI3-Kinase/AKT pathway are well established to antagonize
each other at various points, but this study suggests that the phospho-state of SRp30a and
the alternative splicing of caspase 9 may well be a key point and a cellular biostat for
whether a cell undergoes apoptosis/senescence or is transformed to a malignant phenotype.
How caspase 9b is acting to drive tumorigenic capacity is more of an enigma.
Whereas the role of caspase 9b in circumventing the p53 knockdown requirement is
obvious from the work of Lowe and co-workers, how caspase 9b is important in the
development of anchorage-independent growth is completely unclear. As we have
demonstrated, stable or transient removal of caspase 9b using shRNA blocked the ability
of E746-A750 del EGFR-expressing HBEC-3KT cells to induce anchorage-independent
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growth. This can likely not be attributed to the blockade of an initiator caspase such as
caspase 9a, and suggests a role in cell signaling for caspase 9b. The possibility that caspase
9b acts as a signaling molecule has been described in the literature by Latchman, D.S. and
co-workers170. Specifically, this laboratory group showed that ectopic expression of
caspase 9b induced the activation of NF-θB irrespective of caspase activation as a pancaspase inhibitor could not elicit the same effect170. Furthermore, this group demonstrated
that only the CARD domain was required for this effect. Activation of NF-θB by caspase
9b expression ―fits‖ well with cooperation with k-Ras mutations for the induction of
cellular transformation based on the findings of Baldwin and co-workers. This laboratory
group showed in several different ways that NF-kB activation enhances the ability of
oncogenic Ras to induce cellular transformation253,254. Coupled with the knowledge that
EGFR overexpression/mutation leads to both cooperation with oncogenic ras in cellular
transformation and NF-θB activation, a role for caspase 9b in these pathways important for
oncogenesis is logical. Furthermore, increased expression of caspase 9b is conferred by
EGFR signaling. Thus, caspase 9b may act as a scaffolding protein to elicit downstream
signaling events and having a role outside the simple inactivation of caspase 9a. This
possibility is far from inconceivable as initiator pro-caspases such as caspase 8 and 2 are
suggested to play roles in the recruitment cell survival factors such as PI3-Kinase
subunits255-257. Although these caspases have roles in extrinsic pathways of programmed
cell death, caspase 9b may be playing an analogous role in survival signaling to block the
intrinsic pathway of programmed cell death. This would suggest that the alternative
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splicing of both caspase 8 and 2 (both of which have dominant-negative splice variants)
may play roles in cell survival signaling as well.
In conclusion, the presented study reports several major findings taking a
comprehensive approach. First, the dysregulation of the alternative splicing of caspase 9
toward a pro-survival phenotype was confirmed in a large sample size of non-small cell
lung cancers as well as individual cell lines. Second, a survival/mitogenic pathway
involving PI3-Kinase and Akt was shown to be upstream in regulating this distal splicing
mechanism. Third, EGFR overexpression/mutation affected the alternative splicing of
caspase 9 to produce caspase 9b via this survival pathway. Lastly, the phospho-state of
SRp30a was shown to regulate this distal mechanism via Akt signaling. Therefore, the
presented study demonstrates a novel and key distal mechanism in NSCLC and provides a
slew of new target mechanisms for the development of therapeutics to combat one of the
deadliest cancers in the world.
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